PIP-LSD1 阻害剤結合分子の合成と生物活性評価 by QIN, Rui & 覃, 睿
   
Synthesis of PIP-LSD1 Inhibitor Coupled Molecules 
and Evaluation of Their Bioactivities 
PIP-LSD1 阻害剤結合分子の合成と生物活性評価 
 
Laboratory of Pharmaceutical Chemistry 
Graduate School of Pharmaceutical Sciences, Chiba University 
 
2019 
 
Qin Rui 
 
 
 1 
Contents 
 
Abbreviations .................................................................................................... 3 
Introduction ....................................................................................................... 5 
a. Introduction of pyrrole-imidazole polyamides (PIPs) ................................... 5 
b. Introduction of lysine-specific demethylase (LSD1) .................................... 9 
Chapter I Synthesis of NCD38-PIP hybrid molecules and evaluation of their 
bioactivities ..................................................................................................... 12 
1-1 Introduction ........................................................................................ 12 
1-2 Molecular design of NCD38-PIP hybrid molecules ................................. 13 
1-3 Synthesis of NCD38-PIP hybrid molecules ............................................. 15 
1-3.1 Synthesis of NCD38 type LSD1 inhibitor ..................................... 15 
1-3.2 Synthesis of NCD38-PyPyPyPy hybrid molecules ......................... 18 
1-3.3 Synthesis of NCD38-PyImPyPy hybrid molecules ........................ 19 
1-4 Bioactivities of NCD38-PIP hybrid molecules ........................................ 20 
1-4.1 Inhibition activity of NCD38 type LSD1 inhibitor ......................... 20 
1-4.2 Inhibition activity of NCD38-PIP hybrid molecules ....................... 22 
1-4.3 ChIP-seq analyses and RNA-seq analyses of NCD38 type LSD1 
inhibitor ............................................................................................ 23 
1-4.4 ChIP-seq analyses and RNA-seq analyses of NCD38-PyPyPyPy .... 25 
1-4.5 ChIP-seq analyses and RNA-seq analyses of NCD38-PyImPyPy .... 27 
1-5 Discussion .......................................................................................... 29 
Chapter II Synthesis of Simplified -PIP Hybrid Molecules and evaluation of their 
bioactivities ..................................................................................................... 30 
2-1 Introduction ........................................................................................ 30 
2-2 Molecular Design of Simplified -PIP Hybrid Molecules........................... 31 
2-3 Synthesis of Simplified -PIP Hybrid Molecules ...................................... 31 
2-3.1 Synthesis of Simplified LSD1 Inhibitor ........................................ 33 
2-3.2 Synthesis of Simplified LSD1-PIP Dimer Hybrid Molecules .......... 35 
2-3.3 Synthesis of Simplified LSD1-PIP Teramer Hybrid Molecules ....... 36 
2-3.4 Synthesis of simplified LSD1-PIP teramer (Dp) hybrid molecules .. 37 
2-4 Bioactivities of simplified LSD1-PIP hybrid molecules ........................... 37 
2-4.1 Inhibitory activity of aimplified LSD1-PIP hybrid molecules .......... 37 
 2 
2-4.2 EMSA analyses of simplified LSD1-PyPyPyPy (Dp) Hybrid 
Molecules .......................................................................................... 39 
2-5 Discussion .......................................................................................... 40 
Conclusions ..................................................................................................... 41 
Experimental Section ........................................................................................ 43 
References ....................................................................................................... 72 
Publication ...................................................................................................... 75 
Acknowledgement ............................................................................................ 76 
 
  
 3 
Abbreviations 
 
A adenine 
Ac acetyl 
Ar aryl group 
Bn benzyl 
Boc tert-butoxycarbonyl group 
bp base pair 
C cytosine 
cat. Catalyst 
Cbz benzyloxycarbonyl group 
DMAP 4-(dimethylamino)pyridine 
DMF N,N-dimethylformamide 
DNA deoxyribonucleic acid 
Dp Dimethyl amino pripyl amide 
DPPA di-phenylphosphoryl azide 
EDCI N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
eq equivalent 
Et ethyl 
Et2O diethyl ether 
EtOAc ethyl acetate 
FAD flavine adenine dinucleotide 
G guanine 
h hour(s) 
HATU 1-[ Bis( dimethylamino) methylene] -1H-1,2,3-triazolo[4,5-b] 
pyridinium 3-oxide hexafluorophosphate 
HDMs histone demethylases 
HMTs histone methytransferases 
HOBT 1-hydroxybenzotriazole 
HPLC high performance liquid chromatography 
HRMS high resolution mass spectrum 
Hz hertz 
iPr isopropyl 
 4 
IR infrared 
J coupling constant (in NMR) 
LSD1 lysine-specific demethylase-1 
M mol/L 
Me methyl 
min minute(s) 
mp melting point 
NMR nuclear magnetic resonance 
Ns nosyl group 
Nu nucleophile 
PCPA trans-2-phenyl cyclopropylamine 
Ph phenyl 
PIP pyrrole imidazole polyamide 
PTMs post-translational modification 
quant. quantitative yield 
rt room temperature 
T thymine 
tBu tert-butyl 
δ chemical shift in parts per million downfield from tetramethylsilane 
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Introduction 
 
a. Introduction of pyrrole-imidazole polyamides (PIPs)  
 
It has been developed decades of years on drugs and therapeutics which targeted 
DNA, especially in oncology, and became a mainstay in recent days for their broad 
utilizations and remarkable efficacy. [1-2] As we know, deoxyribose nucleic acid (DNA) 
is a class of molecule playing initial roles in genetic activities, which performing as 
the essential storage media of genetic code and also conducting characterized 
chemically including encoding, transcription and many other functions in organisms. 
There are two fundamental motifs carrying the genetic information, one is four kinds 
of nucleobases within the helical structure, adenine (A), guanine (G), cytosine (C), 
and thymine (T), which tell apart the single nucleotide building blocks from tiny 
variant; the other is the deoxyribose sugar motifs which contain 5’ and 3’ hydroxyl 
groups oriented the DNA strand.  
The specific recognitions of the DNA by certain natural or artificial molecules to 
acquire genetic information that storage in the double helix structure have become an 
ultimate challenge for worldwide researchers. From the ancient days, it has natural 
proteins evolved with minor changes that were occurred in their surface to enable the 
recognition of DNA. The changed surface of evolved protein cooperated or combined 
with DNA perfectly following the stringent rules. In the 1960s, DNA-recognition by 
some small molecules was discovered.[3] Such as dye molecules, which were applied 
for staining, then cell biologists and histologists found that cell nuclei could be bound 
with different dyes specifically. Based on the primeval finding, the “intercalation 
hypothesis” was established on 1961. It was launched by Leonard Lerman who was 
working at the Cambridge MRC laboratory. The discovery of “intercalation 
hypothesis” engendered a myriad of a breakthrough on DNA-targeted drugs through 
the biophysical, biostructural and biochemical evolvements.[4] One of them is 
actinomycin D which is a natural product brought profound impacts on the DNA-drug 
recognition field. [3,5-6] 
Later on, in the 1980s, several natural products were found as the DNA minor groove 
binders. [7] In 1985, Dickerson reported netropsin (Fig. 1.1) which combined with 
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DNA on 1:1 stoichiometry. Two years later in 1987, Rich’s group also reported 
distamycin (Fig. 1.1) which combined with DNA on 1:1 stoichiometry.[8] Then in 
1995, another significant study was reported by Ramakrishnan of distamycin A which 
was proved could form a 2:1 complex with DNA through the binding with minor 
groove.[9] The unveiling of the functional molecule of distamycin A prompted 
researchers to achieve more progress on DNA minor groove binders and seek their 
therapeutic application. Besides, many other DNA-binding natural products and 
synthetic DNA minor groove binders were reported (Fig. a.1), for example, 
tallimustine, PNU 160666, brostacillin etc.[10-12] 
 
 
Fig. a.1: Chemical structures of naturally occurring and synthetic hybrid minor 
groove binders. 
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Since it was verified with NMR and X-ray dates that the pivotal target on recognizing 
DNA specifically was not the major groove but the minor groove, increasing efforts 
were made on this field. The development of DNA minor groove conjugates has 
undergone tremendous changes over the past decades. From the natural product 
dystamycin that was found in the very early time, to a class of heterocyclic oligomers 
that can be programmed chemically or biologically, which demonstrated sequence 
specificity and high affinity.  
One of the most striking class of compounds among them is pyrrole-imidazole 
polyamides (PIPs). PIPs is a class of programmable DNA binder, which has a 
preferential affinity for minor groove. Researchers were inspired by two natural 
products netropsin and distamycin A which were reported as the DNA minor groove 
binder in 1985 and 1995 respectively. Both of them have the similarity on structure, 
pyrrole constitutions enable netropsin and distamycin A to interact with A/T-rich 
region, constituted 1:1 DNA-ligand complex. Additionally, distamycin A also could 
form the DNA-binding complex in 2:1 stoichiometry.[7-9] Meanwhile, the molecular 
architectures were demonstrated. Hydrogen bonds and van der Waals (VDW) 
interactions played pivotal roles. The amide nitrogen of pyrrole reactive with the third 
nitrogen of adenine or the second oxygen of thymine via hydrogen bonds, in addition, 
the second carbon-hydrogen of adenine could interact with the third carbon-hydrogen 
of pyrrole through VDW. Based on the clarification of structure, a new hypothesis 
was established by Dickerson’s group. They illustrated a model that substituted the 
nitrogen of N-methylpyrrole for third carbon, for example changing the pyrrole 
moiety to imidazole. As indicated previously, the replaced nitrogen on imidazole 
would proceed to interact with the amino moiety of guanine via hydrogen bond in 1:1 
stoichiometry. They assumed that the generated complex would engage to recognize 
specifically on G/C Watson–Crick base pairs. They also described details on this 
model, which permitted to recognize G/C pairs from A/T pairs, nevertheless, 
recognize G/C pairs from C/G pairs (Fig. a.2).[11]  
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Fig. a.2 Pairing rules for DNA-binding polyamides indicating the hydrogen bonds 
between bases and Py, Im units. 
 
Later on, Dervan’s group pushed the boundaries. They developed a class of 
Distamycin A analogue ImPyPy-dimethylaminopropylamide (ImPyPy-Dp) which 
could bind with minor groove of DNA in 2:1 stoichiometry as a homodimer. [13] The 
ligand was demonstrated that had a high affinity for 5’-TGTTA-3’ in an antiparallel 
way. Strikingly, they exposited the building block of pyrrole and imidazole as the 
orientated moiety which permitted the Py/Py structure recognized A/T and T/A pairs, 
meanwhile the Im/Py combination targeted in G/C pairs, as well as the Py/Im 
combination targeted in C/G pairs. [14] The demonstrated regulation by Dervan’s 
group rendered a tremendous development of recognition on DNA minor groove. 
Numerous relevant works have been done base on the regulation including this work.  
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b. Introduction of lysine-specific demethylase (LSD1)  
 
Along with the development of epigenetics and oncology, details of tumorous 
mechanism were revealed. It was indicated relations between tumorigenesis and 
epigenetic mutations. Histone abnormalities such as histone lysine methylations 
served as a class of key mutation coupled with tumorigenesis. Therefore, increasing 
cancer research has focused on this process.[15] It was also indicated that the 
methylation of histone played a pivotal role in gene-expression as well as gene 
stabilization. Numerous of cancers have been detected procced the mutation.[16] 
Histones are a class of conserved proteins served as the moiety of chromatin of 
eukaryotic cells and prokaryotic cells. In eukaryotic nucleus, histones perform as the 
significant protein component that exists as the unit frameworks which was wrapped 
around by 146 bp of DNA to form the nucleosomes. 8 histone proteins are divided 
into pairs, H4, H3, H2B and H2A. Each of the pairs are surrounded by DNA to form 
globular cores known as nucleosomes and N-terminal tail that protuberant out of the 
histone/DNA region and are accordant with a various range of post-translational 
modifications, such as methylation, acetylation, ubiquitination and SUMOylation 
(SUMO: .Small Ubiquitin-like Modifier) [15-16].  
 
 
Fig. b.1 Schematic representation shows the organization and packaging of genetic 
material. Nucleosome are represented by DNA (grey) wrapped around eight histone 
proteins. 
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According Vincent Allfrey’s studies in the early 1960s, histone modification is also 
known as post-translational modifications (PTMs), which are arrays of modifications 
influence regulatory biological processes included transcriptional activation/ 
inactivation, replication, chromosome packaging, repression and DNA damage/repair 
etc.[17] The PTMs affects gene expression by altering chromatin structure or 
recombinant histone modifiers. Structural studies by X-ray revealed that histone 
amino (N)-terminal tails can protrude from nucleosome region and interact with 
neighbor nucleosomes.[18-19] Thus the modified tails would alter the action modes 
between nucleosomes consequent on affecting the overall chromatin structure. Recent 
decades years, some PTMs have been well defined and understood. Here I will mainly 
describe methylation and demethylation. 
The major site methylation occurs on the side chains of lysines and arginines that 
considered not changing the histone protein, which were just contrary to acetylation 
and phosphorylation. Histone methylation could be mono-, di- or tri-methylation 
manipulated by diverse histone methyltransferases (HMTs), mostly was consequent 
on gene activation or silence.[20] For instance, di/ trimethylation at H3K4 is involved 
in upregulated gene expression whereas methylation at H3K9, H3K27 and H4K20 is 
involved in downregulated gene expression [21]. Besides the methylation at lysine, 
arginine methylation is also playing a vital role in tumorigenesis. For example, 
PRMT5 which is known as a Type II protein arginine methyltransferases (PRMTs) 
was found implicated in the repression of certain tumor suppressor genes such as 
retinoblastoma (RB) tumor suppressors gene, analogously PRMT7 was observed 
upregulated in breast cancer. 
  
Fig. b.2 N-terminal tail modifications of H3 and H4. M = methylated, A = acetylated, 
P = phosphorylated. 
 
Initially, it was thought that methylation was irreversible and dynamic not like other 
histone modifications which are reversible. Whereas a study in 2002 indicated a new 
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pathway of methylation as a thermodynamic and reversible process.[19] The revers 
process was conducted by histone demethylases (HDMs). In 2004, the first 
lysine-specific demethylase (LSD1) was reported by Shi’s group in 2004.[22] 
LSD1 targets lysine 4 histone H3 (H3K4) or lysine 9 of histone H3 (H3K9), catalyzes 
the mono- and di-demethylation but not tri-demethylation through flavin adenine 
dinucleotide (FAD) dependent enzymatic oxidation. In terms of regulation of 
epigenetic gene expression LSD1 plays pivotal roles in various biological process 
such as embryonic development and homeostasis without carry out any alternation in 
DNA sequence.[15] In addition, it has been reported that LSD1 involved the various 
cancers, for example colon cancer, leukemia etc.[15, 25-27] Besides, LSD1 also indicated 
that has potential to implicate in the infection of α- herpesvirus and globin 
disorder.[28-29] Therefore, compounds that inhibit the catalytic activity of LSD1 are 
interesting as chemical tools for studying the functions of LSD1 and as candidate 
therapeutic agents targeting LSD1 .One of the component of LSD1 inhibitor is 
tranylcypromine (PCPA) which is one of the best-studied LSD1 inhibitors and has 
contributed immensely to the understanding of the biology of LSD1. [26,30-33] In recent 
decades，PCPA has been studied by numerous scientists, the biological studies using 
PCPA have contributed immensely to the understanding of the enzyme. Many of these 
studies suggested that LSD1 inhibitor composed by PCPA derivatives could be new 
approaches to pharmacological designs of promising lead drugs for cancer treatment. 
As elucidated regulation of LSD1 inhibitor, an FDA adduct played vital role as an 
electron mediate to permit the compound which contained PCPA moiety inhibitory 
activity. On the other hand, there are improvable properties of developed PCPA-type 
inhibitor including inadequate inhibitory activity and selectivity.[15] Increasing 
researchers have concentrated on improving PCPA-type LSD1 inhibitors. Likewise, 
this work has made several efforts on expend the utility of NCD38 which is one of the 
LSD1 inhibitor, as well as overcome drawbacks in some extent. 
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Chapter I Synthesis of NCD38-PIP hybrid molecules and evaluation of their 
bioactivities 
 
1-1 Introduction 
 
Base on the clarification of pairing rules between PIPs and DNA minor grooves, 
increasing researchers has focused on the preparation of PIPs efficiently. Initially 
Dervan’s group applied solid-phase synthesis on the synthesis of PIPs for they 
claimed that reaction would take more time and go through in harsh conditions. It was 
considered that a splendid advance for the obvious time reducing, hence a myriad of 
work was realized based on this strategy for preparing PIPs.[34-35] In addition, the 
development of a synthetic method using hydrazine resin and nucleophilic cleavage 
reagent was attributed to the produce of multifunctional polyamides.[36] Nevertheless, 
drawbacks of solid-phase synthesis such as unsatisfactory yields and long reaction 
time limited the utilization on synthesis of PIPs.[37] Thus they turned direction to a 
convergent synthesis performed in solution phase which increased the productivity up 
to gram-scale with minimal chromatography. The efficient synthetic methodology 
inspired us to devise our work in solution phase.     
In our laboratory, several studies on synthesis of PIPs have been done. Previous works 
provided an efficient platform to this project. Base on Tor’s work, the developed 
synthetic routes of PIPs units were applied for preparing the PIPs motifs.[38] 
 
Fig. 1.1 Developed synthesis routes of PIPs units 
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1-2 Molecular design of NCD38-PIP hybrid molecules 
 
Specificity is permitted by recognizing the regulations of WW(=A or T) base pairs by 
antiparallel pyrrole-pyrrole units. The imidazole-pyrrole units and pyrrole-imidazole 
units recognize the SS(S=G or C) base pairs, respectively. These outstanding 
properties empowered PIPs as a good delivery material for various regions of genome. 
Besides, it was proved that LSD1 regulates the expression of many important gene 
progression and cell proliferation, aberrant expression of LSD1 has been shown in 
many types of cancers. Therefore, LSD1 inhibitors were considered to be anticancer 
agents.  
In 2013, Suzuki’s group reported effective LSD1 inhibitors such as 1 and 2 
(NCD38).[39] The inhibitor consists of 2 parts, one is a lysine part for enzyme 
selectivity, the other part is PCPA. Especially, the PCPA is the best-studied LSD1 
inhibitor so far. Many studies suggested that LSD1 inhibitor composed by PCPA 
derivatives could be new approaches of leading drugs for cancer treatment.  
Based on these backgrounds, coupled molecules 3a and 3b were designed to expend 
the utility of both NCD38 and PIPs. As shown in Fig. 1.2, we introduced 2 different 
PIPs to NCD38 moiety expected the genomic region-specific recognition could be 
altered. Because NCD 38 was developed as a diastereomeric mixture regarding the 
stereochemistry of cyclopropane unit, we didn’t have enough information on the 
difference of bioactivity between the diastereomers. Therefore, I first planed the 
synthesis of both diastereomers of the inhibitor parts and determined the preferred 
isomer for this study.  
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Fig. 1.2 LSD1 Inhibitors and Designed NCD38–PIP Hybrid Molecules. Chemical 
structure of compounds. Blue rings, red rings, gray balls and hexagons represent 
pyrrole, imidazole, PCPA-Lys unit and linker unit respectively. 
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1-3 Synthesis of NCD38-PIP hybrid molecules 
 
1-3.1 Synthesis of the LSD1 inhibitor Part 
 
In reference to the reported work, we set out our synthesis of LSD1 inhibitor from the 
preparation of a mesylate derivative 4, which was obtained from L-lysine applying the 
known synthetic route (Scheme 1). [39] A commercial reagent of protected lysine was 
applied as the starting material; the carboxylic acid part then was protected by 
benzylamine in the presence of dual condensation reagents of 1-hydroxybenzotriazole 
(HOBT) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) 
under basic conditions. Followed by deprotection of benzyloxycarbonyl group (Cbz) 
under 1 atm hydrogen and 10% palladium on carbon, the obtained amine was then 
converted to alcohol using diazo-reaction which was performed in the presence of 22 
equivalent sodium nitrite, 1 equivalent hydrogen chloride, 5.1 equivalent acetic acid 
and 0.04 M water as solvent. The diazo-reaction did not yield the product efficiently 
as we expected especially in scale-up reaction, while still concurs with the data 
reported in Suzuki’s paper. Consequent on coupling the hydroxy group with 
methanesulfonyl chloride under basic conditions, the preparation of mesylate 
derivative 4 was come to the conclusion. 
 
 
 
 
Scheme 1.1 Preparation of mesylate derivative 4 
 16 
Then, the mesylate derivative 4 was dissolved in dichloromethane and deprotected the 
t-butyloxycarbonyl group (Boc) in the presence of 10 equivalent 4M HCl/dioxane, the 
resulting amine was coupled with the commercial reagent of 3- 
(methoxycarbonyl)benzoic acid 5 using dual condensation reagent of 
1-hydroxybenzotriazole (HOBT) and 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI), both of 
them were applied 1.5 equivalent in DMF generating compound 6 in 56% yield. The 
suspension of mesylate derivative 6 was dissolved in acetone with sodium iodide 
undergoing iodination reaction refluxed for 12 hours produced iodide derivative 7 in 
94% yield.   
 
 
Scheme 1.2 Synthesis of LSD1 inhibitor part (A) 
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Then we planned to coupled iodide derivative 7 with N-2-nosyl (Ns) 
phenylcyclopropylamine 8. There is 2 different stereometric structure of 8. To 
determine the more bioactive structure, the pure enantiomers of 8 was prepared. As 
described above, NCD38 was developed using racemic 
trans-2-Phenylcyclopropylamine.[39] Later in the 2014, Suzuki’s group reported 
another work of synthesis of optically pure NCD serious inhibitors and evaluated their 
LSD1 inhibitory activities.[40] The data reported in this paper suggested that the 
compounds with 1S, 2R stereochemistry regarding the PCPA unit would be more 
bioactive compounds towards LSD1 inhibition activities. 
According to the 2 works as references, our work was also conducted the optical 
resolution of racemic 8, then coupled the 2 enantiomers which was (1S, 2R)-8 and (1R, 
2S)-8 with lysine moiety of compound 7, generating diastereomers 9 and 11.[41] The 
following study of LSD1 inhibitory activity revealed that the 2 diastereomer 9 and 11 
had different LSD1 inhibitory activity (See Fig 1.3). The 2 enantiomers were coupled 
with 1.5 equivalent of iodide derivative 7 and 2 equivalent of K2CO3 in DMF to result 
compounds 9 and 11 in 91% yield and 76% yield, respectively. Another synthesis trail 
of compound 9 which started from mesylate derivative 6 could also had possibility be 
utilized. However, a pre-experiment result indicated that efficiency of this trail was 
less satisfactory. Then compound 9 and 11 were followed a deprotection reaction of 
Ns group using a silica-supported thiol (SiliaMetS® Thiol), the resulting compounds 
10 and 12 were generated in 62% yield and 76% yield, respectively.  
 
 
Scheme 1.3 Synthesis of LSD1 inhibitor part (B) 
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1-3.2 Synthesis of NCD38-PyPyPyPy hybrid molecules 
 
Compound 9 was hydrolyzed under basic conditions, turning the methyl ester moiety 
to the carboxylic acid. Then it was condensed with a -alanine dimer 13 to inaugurate 
a spacer unit between the LSD1 inhibitor unit and PIP unit. The reaction was 
conducted in the presence of 2 equivalent of PyBOP, 4 equivalents of N, 
N-diisopropylethylamine (DIPEA) and 2 equivalents of -alanine dimer 13 in DMF, 
adduct 14 was afforded in 76% in 2 steps from 9. Then compound 14 was hydrolyzed 
under basic conditions, turning the methyl ester moiety to the carboxylic acid. The 
tetramer consisted by pyrrole unit (HCl·NH2-PyPyPyPy-COOMe) 15 was coupled 
with the obtained carboxylic acid in the presence of 2 equivalents of PyBOP in DMF 
to obtain the adduct 16 in overall 75% yield in 2 steps. The nosyl group of compound 
16 was removed to obtain NCD38-PyPyPyPy hybrid molecule 3a in 65% yield. 
 
Scheme 1.4 Synthesis of NCD38-PyPyPyPy hybrid complex 
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1-3.3 Synthesis of NCD38-PyImPyPy hybrid molecules 
 
Likewise, another hybrid molecules 3b was prepared in the same way as 3a.  
The compound 14 was hydrolyzed under basic conditions, turning the methyl ester 
moiety to the carboxylic acid. Then the tetramer consisted by 3 pyrrole units and 1 
imidazole unit (HCl·NH2-PyImPyPy-COOMe) 17 was coupled with the obtained 
carboxylic acid in the presence of 2 equivalents of PyBOP in DMF to obtain the 
adduct 18 in overall 72% yield in 2 steps. The nosyl group of compound 18 was 
removed to obtain NCD38-PyImPyPy hybrid molecule 3b in 55% yield. 
 
 
 
 
 
Scheme 1.5 Synthesis of NCD38-PyImPyPy hybrid complex 
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1-4 Bioactivities of NCD38-PIP hybrid molecules 
 
1-4.1 Inhibition activity of LSD1 
 
Inhibitory activities of LSD1 were assessed in gradient concentration as 9.6%, 19.4% 
and 22.9% using 20 μM of compound 2 (developed NCD38 molecule),[39] 10, and 12, 
respectively. (Fig. 1.3) When using 1 μM of compound 2, 10, and 12, the inhibitory 
activities were detected as 26.2%, 32.7% and 51.4%, respectively. The consequence 
suggested obviously that both of the 2 diastereomeric compounds of 10 and 12 
exhibited LSD1 inhibitory activities, in addition, the 2 diastereomeric compounds 
inhibited LSD1 as the similar level of the parental compound 2. Furthermore, it was 
detected that when applied in concentration as 1 μM (P = 0.029), 5 μM (P = 0.036) 
and 10 μM (P = 0.046), compared with both parental compound 2 and compound 12, 
diastereomeric compound 10 revealed apparently stronger LSD1 inhibitory activity. 
On the contrary, no obvious discrepancy at 20 μM (P = 0.38) was detected. The 
consequences implied that the LSD1 inhibitory activity of NCD38 could be enhanced 
by merged the optical resolution into synthesis route. Moreover, the bioactivity results 
guided us explicitly that the compound with 1S, 2R stereochemistry regarding the 
PCPA unit: compound 10 was a better candidate for further studies. Therefore, 
compound 9 was mainly used as a key synthetic intermediate for this study. 
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Fig. 1.3 Inhibition of LSD1 activity by the compounds in vitro. LSD1 activities 
were assessed using an LSD1 activity assay kit. Relative LSD1 activities are shown 
as bars filled with white, light grey, grey, black, dots and slashed lines in presence 
0.1, 0.5, 1, 5, 10 and 20 μM of the compounds, respectively. LSD1 activities were 
estimated by comparison with 1% DMSO control as 100%. Data represent the 
mean of three independent replicates ± SD. * P < 0.05. 
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1-4.2 Inhibition activity of NCD38-PIP hybrid molecules 
 
In the same way, LSD1 activities of 3a and 3b were estimated. The LSD1 activity was 
assessed with LSD1 activity assay kit in 6 different concentrations of the compounds 
3a and 3b, respectively. DMSO was used as negative control for LSD1 inhibitor. The 
inhibitory activities of LSD1 was tested using 1% DMSO as negative control. Error 
bars, standard deviation of the means of triplicate samples. As the bar chart indicated 
clearly that both 3a and 3b inhibited LSD1 activities were levels similar to the 
parental NCD38.  
 
 
Fig. 1.4 Inhibition of LSD1 activity by conjugated 3a and 3b in vitro. LSD1 
activities were assessed using an LSD1 fluorometric drug discovery kit. Relative 
LSD1 activities are shown as bars filled with white, light grey, grey, black, dots and 
slashed lines in presence 0.1, 0.5, 1, 5, 10 and 20 μM of the compounds, 
respectively. LSD1 activities were estimated by comparison with 1% DMSO 
control as 100%. Data represent the mean of three independent replicates ± SD. 
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1-4.3 ChIP-seq analyses and RNA-seq analyses of NCD38 
 
Initially, we performed the genome-wide analysis for histone modification alterations 
induced by the NCD38 (Fig. 1.5. A & B). We carried out ChIP-seq analysis for 
H3K4me2 H3K27ac, and RNA-seq analysis for colon adenocarcinoma cells 
incubated in the presence of NCD38 as the inhibitor for 1 month. As the figure 
showed, 103 and 458 regions exhibited higher than 3 times upregulation in the 2 
antibodies levels, respectively, in NCD38 processed cells compared with negative 
control processed cells. RNA-seq analysis implied that the expression of regulation as 
well as the ChIP-seq peaks of the 2 antibodies which were immensely upregulated in 
NCD38 processed cells compared with negative control processed cells. The 
consequences implied that cells processed with NCD38 was upregulated the level of 
the 2 antibodies, consequent in upregulated of DNA near the activation regions. 
In addition, 6 base pairs DNA sequences within 250 base pairs were analyzed. (Fig. 
1.5. C) As a result of investigating in 6 base unit and listing up in order of frequency, 
it is suggested that CG-rich sequence is high in NCD38 treatment system. 
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Fig. 1.5 (A) Heat maps showing the read densities of ChIP-seq within ± 5 kb 
around the center position of ChIP-seq peaks. Whereas increase of H3K4me3 level 
was hardly observed, 103 and 458 regions showed >3-fold increase of H3K4me2 
and H3K27ac levels, respectively. Expression of genes nearest to the H3K4me2 and 
H3K27ac peaks were significantly upregulated (P = 0.03 and P = 3 × 10−10, 
respectively, t-test). (B) RNA-seq analysis in each activation region. Each 
activation region had a dominant rise in gene expression levels up to. (C) 6-bp 
DNA sequences within 250 bp from the center of the increased H3K27ac peaks are 
shown. GC-content of top 10 6-bp sequences was as high as 80% ± 9% . 
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1-4.4 ChIP-seq analyses and RNA-seq analyses of NCD38-PyPyPyPy   
 
Then, the compound 3a was analyzed in the say way. (Fig. 1.6 A & B). We carried out 
ChIP-seq analysis for the same antibodies. The RNA-seq analysis was performed 
using colon adenocarcinoma cells incubated in the presence of compound 3a for 1 
month. The ChIP-seq analyses indicated that compared with the parental inhibitor, 
compound 3a was showed less regions of more than 3 times upregulation in H3K27ac 
levels. 
RNA-seq analysis implied that the expression of regulation as well as the ChIP-seq 
peaks of the H3K27ac antibodies which were immensely upregulated in the 
compound 3a processed cells compared with negative control processed cells. 
Interestingly, all of the 234 regions had no overlap of activated regions between 
NCD38 and compound 3a treated cells. The sequences analysis implied that all the 
top 10 sequences were AT-rich region, Compared with NCD38 treated cells, the 
appearance of GC-rich sequences significantly downregulated in the compound 3a 
treated cells. 
Then we detected whether the compound 3a had priority of targeting AT-rich regions. 
6 base pairs DNA sequences within 250 base pair were analyzed.  
Surprisingly, the top 10 sequences were AT-rich regions, meanwhile, expression of 
GC-rich regions was downregulated compared with the performance of parental 
inhibitor treated cells. The performance of 6 base pairs sequences of G or C indicated 
that there was a clearly downregulated in the compound 3a treated cells (P < 1 × 
10−15). On the other hand, performance of 6 base pairs sequences of A or T indicated 
that there was a clearly upregulated in the compound 3a treated cells (P < 1 × 10−15). 
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Fig. 1.6 (A) Heat maps showing read densities of H3K4me2, H3K4me3, and 
H3K27ac within ± 5 kb around H3K27ac-increased regions in enhancers and other 
regions. Genes nearest to the H3K27ac peaks in other regions were significantly 
upregulated (P = 9 × 10−10), while those in enhancer regions tended to be 
upregulated (P = 0.053). (B) RNA-seq analysis in each activation region. Each 
activation region had a dominant rise in gene expression levels up to. (C) 
Frequencies of appearance of 6-bp sequences within 250 bp from the center of the 
increased H3K27ac peaks. All the top 10 sequences were WWWWWW. 
  
‐5k +5k ‐5k +5k‐5k +5k ‐5k +5k
‐5k +5k ‐5k +5k ‐5k +5k ‐5k +5k
‐0.3
‐0.2
‐0.1
0
0.1
0.2
0.3
(n  = 150)
*P= 2x10  ‐11
DMSO P4‐N
Lo
g2
 fo
ld
‐ex
pr
es
si
on
0 20 40 60
Frequency
TTATTTTTTATTTTTAAATATTTTATATTTTTAAAAGAATGGAATGGAAAATATAAAAAT
GGCGCG
CCGCCGCCCGCGGCCCGCCGCCCGGGGCGCGGGCCCGCCCCGCCCGCC
GGCGCC
A B C
H3K4me2
DMSO P4-NCD38
H3K27ac
DMSO P4-NCD38
H3K4me2
DMSO P4-NCD38
H3K27ac
DMSO P4-NCD38
H3K4me2
(n = 1)
H3K27ac
(n = 234)
 27 
1-4.5 ChIP-seq analyses and RNA-seq analyses of NCD38-PyImPyPy 
 
Also, we analyzed the compound 3b in the same way (Fig. 1.7 A & B). We carried out 
ChIP-seq analysis for the same antibodies. The RNA-seq analysis was performed 
using colon adenocarcinoma cells incubated in the presence of compound 3a for 1 
month. The ChIP-seq analyses indicated that compared with the parental inhibitor, 
compound 3b was showed less regions of more than 3 times upregulation in the 2 
antibodies’ levels. The majority (89%) of 82 upregulated regions of H3K27ac were 
not located in promoter regions. Besides, overlap of activation regions between 
parental inhibitor and the compound 3b treatment cells was not detected. The 
consequences implied that cells processed with the compound 3b could not 
upregulated significantly the level of DNA regulation close to H3K27ac peaks (P = 
0.1), compared with DMSO treated cells. Then we detected whether the compound 3b 
had priority of targeting WWCGWW regions. 6 base pairs DNA sequences within 250 
base pair were analyzed. The consequences implied that top 5 to 10 sequences contain 
GC were detected as 40% ± 4% and 55% ± 6%, respectively, however, it was lower 
than the performance that cells treated by NCD38. Meanwhile, WWCGWW sequence 
was not detected in top 10 sequences, probably due to the less frequent appearance of 
GC sequence then the expectation. 
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Fig. 1.7 (A) Heat maps showing the read densities of ChIP-seq within ± 5 kb 
around the center position of ChIP-seq peaks. (B) RNA-seq analysis in within ± 5 
kb around the center position of H3K4me2 and H3K27ac. Less number of regions 
(97 and 82) showed more than 3-fold increases in H3K4me2 and H3K27ac levels, 
respectively, compared with treatment by parental NCD38. Expression of genes 
nearest to these H3K4me2-increased and H3K27ac-increased peaks were not 
significantly up-regulated. (C) Frequencies of appearance of 6-bp sequences within 
250 bp from the center of the increased H3K27ac peaks. GC-contents of top 5 and 
top 10 sequences decreased to 40% ± 4% and 55% ± 6%, respectively  
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1-5 Discussion 
 
We successfully synthesized LSD1 inhibitor–pyrrole-imidazole polyamide conjugates 
for region-specific alterations of histone modification. Based on the synthestic route 
of NCD38 which developed by Suzuki’s group, we prepared the NCD38-like LSD1 
inhibitor part efficiently. A (1S,2R) - trans - 2 - phenyl cyclopropylamine unit was 
conjugated with an L-lysine derivative using a nosyl group as a functional protecting 
group (Ns strategy). Coupling of LSD1 inhibitor moiety with 2 different 
pyrrole-imidazole polyamide tetramers was executed through amide bond formation. 
Additionally, LSD1 activities of 3a and 3b were estimated. The LSD1 activity was 
assessed with LSD1 activity assay kit in 6 different concentrations of the compounds 
3a and 3b, respectively. As the results indicated clearly that both 3a and 3b inhibited 
LSD1 activities. The levels of inhibition were similar to that of the parental NCD38.  
As applied the conjugation of NCD38-like LSD1 inhibitor with two different PIP 
tetramer units, we detected and analyzed the alternation of epigenetic regions by 
NCD38 and two different hybrid molecules, compound 3a which is NCD38-β2PPPP 
and compound 3b which is NCD38-β2PIPP. The recognition of specific regions had a 
significant alternation from the GC-rich regions to the AT-rich regions. The 
consequences indicated that the two different hybrid molecules targeted various 
sequences, indicating that the sequence-specific recognition of NCD38-PIP 
conjugates alternated from GC-rich regions to AT-rich regions. 
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Chapter II Synthesis of Simplified -PIP Hybrid Molecules and evaluation of 
their bioactivities 
 
2-1 Introduction 
 
LSD1 was found to be a highly conserved flavin-containing amino oxidase homolog 
that specifically removes the mono- and di-methylated lysine at lysine 4 or lysine 9 of 
H3. Speaking of histone methylation, which was verified as a reversible process. 
Modern science clarified that the major site of this process occurs on the side chains 
of lysines and arginines. Generally, arginine is involved in gene activation and histone 
methyltransferases. By comparison, lysine sites can have multiple effects on 
chromatin function. Therefore, increasing effort has been done on this field. 
As “methyl eraser”, LSD1 regulates the expression of many important genes’ 
progression and cell proliferation. Aberrant expression of LSD1 has been shown in 
many types of cancers. In particular, LSD1 expression is upregulated in bladder, small 
cell lung, and colorectal clinical cancer tissues when compared with the 
corresponding nonneoplastic tissues. LSD1 has also been shown to be overexpressed 
in some breast cancers and may function as a biomarker of the aggressiveness of the 
disease. 
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2-2 Molecular Design of Simplified -PIP Hybrid Molecules 
 
It has been proved by previous studies that PCPA derivatives exhibit LSD1 inhibitory 
activity. It also suggested that the PCPA itself has several shortages such as low 
affinity and selectivity against LSD1. Compared with LSD1, PCPA inhibited MAOs 
(monoamine oxidases) which are also FAD-dependent enzymes preferentially. Thus, 
Suzuki and coworkers developed NCD38 type LSD1 inhibitor which was designed 
with a lysine moiety as the PCPA carrier. The modified lysine moiety was initially 
designed to serve a selective inhibitor for LSD1. They examined the IC50 values of 
PCPA and NCD38 against LSD1, MAO A and MAO B. The IC50 value of PCPA 
against LSD1 was higher than MAOs, while NCD38 inhibited LSD1 with far more 
efficiency as expected.[39]  
 IC50 (M) 
 LSD1 MAO A MAO B 
PCPA 31 2.5 2.4 
NCD38 0.59 >100 >100 
Table 2.1 IC 50 values of compounds against LSD1, MAO A and MAO B 
 
As mentioned previously, PIPs have been used to drive self-assembly on 
nano-platform based on the specific recognition of DNA via Watson-Crick 
base-pairing regimes. It is also proved that MAOs mainly localized in mitochondrial 
outer membranes.[42] Therefore the complex combined with PIP would deliver PCPA 
to nucleus over mitochondrial outer membranes to serve selectivity of LSD1 naturally. 
This mean the lysine moiety in NCD38-type inhibitor would not be necessarily 
important when using PIP unit-coupled molecules. Thus, we hypnotized a simplified 
LSD1 inhibitor, with both of PCPA and a simple alkyl side chain as linker moiety. It is 
worth to mention that we designed the linker part without cumbersome substituents, 
such as benzyl amino group and chloro-benzyl amino group. 
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Fig. 2.1 (A) Molecular structure of NCD38-PIP complex; (B) Molecular structure of 
simplified LSD1 inhibitor-PIP complex 
  
A B 
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2-3 Synthesis of Simplified -PIP Hybrid Molecules 
 
2-3.1 Synthesis of Simplified LSD1 Inhibitor 
 
According to our design of simplified LSD1 inhibitor, it is constituted by PCPA and 
linker moieties. Therefore, we set out our synthesis of simplified LSD1 inhibitor from 
the preparation of these two parts respectively. Firstly, a commercial reagent of 
2-phenylcyclopropane-1-carboxylic acid 19 was applied as the starting material, in the 
presence of diphenylphosphoryl azide (DPPA) as the azidation reagent, triethylamine 
and tert-butanol, an azidation reaction was conducted undergoing the Curtius 
rearrangement, directed the consequence of Boc protected 
2-phenylcyclopropan-1-amine. The resultant was solved in dichloromethane and 
deprotected the t-butyloxycarbonyl (Boc) group in the presence of 10 equivalent 4M 
HCl/dioxane, afterwards, a 2-Ns group was applied as the protecting group of the 
amine using 1.2 equivalent 2-nitrobenzenesulfonyl chloride under the basic conditions 
to obtain the rac-8 in 50% yield in total 3 steps. Furthermore, the linker part was also 
prepared according to the known synthetic methods. 
Commercial reagent of oxepan-2-one was used as the starting material, a ring-opening 
reaction was executed in the presence of concentrated sulfuric acid, refluxed at 80 C 
for 3 hours. The residue then followed an iodination reaction to give the compound 21 
in 72% yield in 2 steps. 
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Scheme 2.1 Synthesis of simplified LSD1 inhibitor (A) 
 
All the reactions and compounds elucidated above is reported in previous of other 
researchers. We compared known analysis information with our detected ones to 
identify these compounds. 
Since the preparation of PCPA and linker substrates were achieved, a nucleophilic 
reaction was performed between the nitrogen of rac-8 and -carbon of 21 to couple 
the 2 moieties together under basic conditions. The ester part of the obtained adduct 
was hydrolysis using the solvent of lithium hydroxide and refluxed in 50 C for 14 
hours to generate the target compound 22 in 53% yields in 2 steps. 
 
 
 
Scheme 2.2 Synthesis of simplified LSD1 inhibitor (B) 
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2-3.2 Synthesis of Simplified LSD1-PIP Dimer Hybrid Molecules 
 
The prepared carboxylic acid derivative 22 was coupled with hydrochloride of PIP 
dimer to introduce the linker part and PCPA part of LSD1 inhibitor. The coupling 
reaction was conducted in the presence of 2 equivalent HATU, 6 equiv of i-Pr2NEt 
and 1 equivalent of hydrochloride of PIP dimer in DMF, at room temperature for 24 
hours. The precursor molecule of the target hybrid compound was obtained in 64% 
yield. Then the precursor molecule followed a deprotection reaction of Ns group 
using a thiophenol and K2CO3 in DMF, the resulting compounds 23 was generated in 
60% yield. Compound 24 and 25 was prepared using the same method as that for 
compound 23. See more information at experimental section. 
 
 
Scheme 2.3 Synthesis of simplified LSD1-PIP dimer hybrid molecules 
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* Compound 24 did not use PIP amine hydrocloride but PIP amine.
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2-3.3 Synthesis of Simplified LSD1-PIP Teramer Hybrid Molecules 
 
Likewise, we synthesized another 2 different of LSD1-PIP hybrid complexes. The 
prepared carboxylic acid derivative 22 was coupled with hydrochloride of PIP 
tetramer to introduce the linker part and PCPA part of LSD1 inhibitor. The coupling 
reaction was conducted in the presence of 2 equivalent HATU, 6 equivalents of 
i-Pr2NEt and 1 equivalent of hydrochloride of PIP dimer in DMF, at room 
temperature for 24 hours. The precursor molecule of the target hybrid compound was 
obtained in 63% yield. Then the precursor molecule followed a deprotection reaction 
of Ns group using a thiophenol and K2CO3 in DMF, the resulting compounds 23 was 
generated in 61% yield. Compound 27 was prepared using the same method as that 
for compound 26. See more information at experimental section. 
 
 
Scheme 2.4 Synthesis of simplified LSD1-PIP tetramer hybrid molecules 
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2-3.4 Synthesis of simplified LSD1-PIP teramer (Dp) hybrid molecules 
 
In addition, a modification of C-terminal of the simplified LSD1-PIP tetramer hybrid 
molecules was performed. After hydrolysis of the ester part in compound 26 under 
basic conditions, the obtained carboxylic acid derivative was coupled with N, 
N-dimethylpropane 1,3-diamine which may enhance the ability of cell permeability.[43] 
When the reaction was performed using 2 equivalent of  HATU, 5 equivalent of  N, 
N-dimethylpropane 1,3-diamine in DMF at room temperature, compound Ns-28 was 
obtained in 65% yield. Then compound Ns-28 was followed a deprotection reaction 
of Ns group using a thiophenol and K2CO3 in DMF, the resulting compound 28 was 
generated in 61% yield. Compound 29 was prepared using the same method as that 
for compound 28. See more information at experimental section. 
 
Scheme 2.5 Synthesis of simplified LSD1-PIP Teramer (Dp) hybrid molecules 
 
2-4 Bioactivities of simplified LSD1-PIP hybrid molecules 
 
2-4.1 Inhibitory activity of aimplified LSD1-PIP hybrid molecules 
 
Inhibition of LSD1 activities were determined in vitro. The commercial LSD1 
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inhibitor of GSK-LSD1 (Fig. 2.2) was applied as the positive control. GSK-LSD1 is 
an irreversible, mechanism-based inhibitor of LSD1 which induces gene expression 
changes in cancer cell lines and inhibits cancer cell line growth. It is also implied that 
GSK-LSD1 has permitted itself as a chemical probe as part of the SGC epigenetics 
initiative.[44] 
In our vitro test, GSK-LSD1 inhibits LSD1 with an IC50 of 64.794 nM with 6.907 
standard error. 3 different simplified LSD1-PIP dimer complexes exhibited IC 50 
various from 165.114 to 214.198 with standard error below 50. Whereas the IC 50 
values of 4 different simplified LSD1-PIP tetramer complexes no matter ester or Dp 
C-terminal revealed slight upgraded various from 225.76 to 336.202 with standard 
error below 50. It was implied that LSD1-inhibiting activities of 7 types of simplified 
LSD1-PIP hybrid molecules were marginally down down-regulated compared with 
the positive control. Nevertheless, these compounds still presented considerable 
inhibitory activity of LSD1. 
 
 
Compounds IC 50 Std. Error 
GSK-LSD1 64.794 6.907 
Simplified LSD1-PyPy-Me 173.755 37.099 
Simplified LSD1-PyIm-Me 165.114 25.391 
Simplified LSD1-ImPy-Me 214.198 48.713 
Simplified LSD1-PyPyPyPy-Me 225.76 44.659 
Simplified LSD1-PyPyImPy-Me 336.202 32.678 
Simplified LSD1-PyPyPyPy-Dp 375.14 49.61 
Simplified LSD1-PyPyImPy-Dp 336.202 32.678 
 [nM] 
Table 2.2 IC 50 values of compounds against LSD1 
 
 
 
Fig. 2.2 Chemical structure of GSK-LSD1 inhibitor 
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2-4.2 EMSA analyses of simplified LSD1-PyPyPyPy (Dp) Hybrid Molecules 
 
Furthermore，electrophoretic mobility shift assays (EMSA) analyses was conducted to 
test the specific recognition of WWWWWW or WWCGWW sequence by the 
simplified LSD1-PyPyPyPy (Dp) hybrid molecule.        
It was performed for double strand DNA (dsDNA) in presence of compound 28. It 
was demonstrated that compound 28 bound to dsDNA containing WWWWWW. 
Whereas the recognition of dsDNA containing WWCGWW sequences could not been 
detected.  
 
Fig. 2.4 EMSA analysis for double strand DNA (dsDNA) in presence compound 28, 
vehicle control (lane 5: 1% DMSO).  
  
0    20    0       20    [M]
P4 P4
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2-5 Discussion 
 
In this section, we designed a simplified LSD1 inhibitor based on the previous 
researches. Since numerous works implied that PCPA derivatives exhibited LSD1 
inhibitory activity, albeit possessed some shortages such as low affinity and selectivity 
against LSD1. To improve these shortcomings, various of complexes combined PCPA 
with PIPs was prepared.  
As the design of simplified LSD1 inhibitor, the synthetic route was shortened 
strikingly compared with the NCD38-type inhibitor. In terms of the synthesis of 
NCD38-type inhibitor, included the preparation of substrate of compound 4 and 
optical resolution of compound 8, total 14 steps were necessary. On the contrary, 
synthesis of the simplified LSD1 inhibitor started from a commercial reagent 
processed 7 steps to obtain the target inhibitor carboxylic acid 22. The synthetic 
efficiency was remarkably increased. I established an applicable platform for the 
future works.  
In addition, the IC 50 values of 7 types of simplified LSD1-PIP hybrid molecules 
were measured, implying that LSD1-inhibiting activities were marginally down 
compared with the positive control. Nevertheless, these compounds still presented 
considerable inhibitory activity of LSD1. Besides, electrophoretic mobility shift 
assays (EMSA) analyses indicated that simplified LSD1-PyPyPyPy (Dp) hybrid 
molecule bound to dsDNA containing WWWWWW, whereas the recognition of 
dsDNA containing WWCGWW sequences could not been detected. 
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Conclusions 
 
In this study, we conducted two parts of studies of LSD1 inhibitors conjugated PIPs 
molecules. In the first part, we prepared NCD38-type inhibitor moiety based on the 
synthetic route of NCD38 which developed by Suzuki’s group. The PCPA unit that 
permitted the whole coupled molecules inhibitory activity was conjugated with an 
L-lysine derivative using a nosyl group as a functional protecting group (Ns strategy). 
Coupling of NCD38-type inhibitor moiety with 2 different pyrrole-imidazole 
polyamide tetramers was executed through amide bond formation. Additionally, 
LSD1 inhibitory activity was assessed using these 2 coupled molecules which are 3a 
and 3b, respectively. As the results indicated clearly that both 3a which is 
NCD38-β2PPPP and 3b which is NCD38-β2PIPP inhibited LSD1 activities. The 
levels of inhibition were similar to that of parental NCD38. Meanwhile, ChIP-seq and 
RNA-seq data of the regions epigenetically altered by parental NCD38 and the two 
different hybrid molecules were analyzed. It was implied that the recognition of 
specific regions had a significant alternation from the GC-rich regions to the AT-rich 
regions. The consequences indicated that the two different hybrid molecules targeted 
various sequences, indicating that the sequence-specific recognition of NCD38-PIP 
conjugates alternated from GC-rich regions to AT-rich regions. 
Furthermore, we hypothesized a simplified LSD1 inhibitor for the following work for 
2 reasons. Firstly, it was reported numerously that PCPA derivatives were LSD1 
inhibitory activity. Besides, the PIPs could enable the hybrid molecules 
region-specific recognitive function whereas the complicated PCPA carrier moiety 
which serve the inhibitor selectivity would be simplified. Thus, LSD1 inhibitor 
composed with PCPA moiety as well as a simpler linker expected a practicable 
inhibitor structure for this work. The alternation of structure significantly shortened 
the synthetic route of LSD1 inhibitor. Compared with the NCD38-type inhibitor 
coupled molecule which was synthesized in total 14 steps. On the contrary, we 
prepared the simplified LSD1 inhibitor started from a commercial reagent processed 7 
steps. The efficiency of preparing inhibitor was remarkably increased. We established 
an applicable platform for the future works.  
Likewise, the IC 50 values of 7 types of simplified LSD1-PIP hybrid molecules were 
implied that LSD1-inhibiting activities were marginally down compared with the 
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positive control. Nevertheless, these compounds still presented considerable 
inhibitory activity of LSD1. Besides, electrophoretic mobility shift assays (EMSA) 
analyses indicated that simplified LSD1-PyPyPyPy (Dp) hybrid molecule bound to 
dsDNA containing WWWWWW, whereas the recognition of dsDNA containing 
WWCGWW sequences could not been detected.  
 
In conclusion, we established an applicable platform of synthesizing LSD1 inhibitor, 
which contains PCPA moiety, coupled PIPs to generated LSD1-PIPs hybrid molecules. 
Applying both developed NCD38-type LSD1 inhibitor and the designed new LSD1 
inhibitor, various LSD1-PIPs hybrid molecules were prepared successfully. Especially, 
the simplified LSD1 inhibitor-PIPs hybrid molecules could be prepared efficiently 
which facilitated the following works such as study of bioactivities significantly. 
Bioactivity assessments of NCD38-PIPs were completed including inhibitory 
activities, ChIP-seq analysis and RNA-seq analysis. Likewise, the simplified LSD1 
inhibitor-PIPs hybrid molecules would be assessed of their bioactivities. LSD1 
inhibitory activities and ChIP-seq analysis of simplified LSD1-PyPyPyPy (Dp) hybrid 
molecule have been done, estimating of the other compounds are ongoing. 
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Experimental Section 
 
General: Infrared (IR) spectra were recorded on a Fourier transform infrared 
spectrophotometer, equipped with ATR. NMR spectra were recorded with a 400 MHz 
spectrometer. Chemical shifts in CDCl3 were reported downfield from TMS (= 0 
ppm) for 1H NMR. For 13C NMR, chemical shifts were reported in the scale relative 
to the solvent signal [CHCl3 (77.0 ppm)] as an internal reference. Positive-ion mass 
spectra were recorded by electrospray ionization (ESI-TOF). Column chromatography 
was performed with silica gel 60N (spherical, neutral, 40–60 m mesh) (Kanto 
chemical) or CHROMATOREX NH-DM1020 (Fuji silysia chemical). Reactions were 
carried out in dry solvent. Other reagents were purified by the usual methods. 
 
Synthesis of 6 
 
 
To a stirred solution of 4 (809 mg, 1.95 mmol) in CH2Cl2 (67.8 mL) at 0 °C was 
added 4M HCl in dioxane (4.9 mL) and the resulting mixture was stirred at room 
temperature. After 1 h, organic solvent was removed to give the corresponding amine 
hydrochloride in a quantitative yield. 
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To a stirred solution of 3-(methoxycarbonyl)benzoic acid 5 (135.1 mg, 0.75 mmol), 
1-hydroxybenzotriazole (HOBt) (101.3 mg, 0.75 mmol), 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) (143.8 mg, 
0.75 mmol), and triethylamine (0.28 mL, 2 mmol) in DMF (2.5 mL) at 0 °C was 
added the obtained amine hydrochloride (175.4 mg, 0.5 mmol). After 17 h, the 
reaction was quenched with sat. aq. NH4Cl solution and diluted with AcOEt. The 
resulting mixture was washed with 1M aq. HCl solution, sat. aq. NaHCO3 solution, 
and brine, and then dried over Na2SO4. After concentration under reduced pressure, 
the residue was recrystallized from AcOEt-hexane to give compound 6 as white solid 
(135 mg, 56% yield). []20D = –9.8 (c = 0.23, CHCl3); Mp. 142–143°C; 1H NMR (400 
MHz, CDCl3)  1.47–1.60 (m, 2H), 1.70– 2.08 (m, 4H), 2.95 (s, 3H), 3.91 (s, 3H), 
4.13–4.25 (m, 2H), 4.36 (dd, J = 5.6 Hz, 14.8 Hz, 1H), 4.46 (dd, J = 5.6 Hz, 14.8 Hz, 
1H), 4.70–4.82 (m, 1H), 7.10–7.37 (m, 7H), 7.43–7.48 (m, 1H), 7.93 (d, J = 8.0 Hz, 
1H), 8.14 (d, J = 8.0 Hz, 1H), 8.38 (d, J = 1.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) 
 21.5, 28.6, 31.9,37.3, 43.5, 52.3, 53.4, 69.6, 127.5, 127.6 (2C), 127.9, 128.6 (2C), 
128.8, 130.5, 131.7, 132.7, 133.9, 137.8, 166.1, 166.5, 171.3; IR (ATR)  1721, 1631, 
1532, 1347, 1252, 1163, 956, 821, 694 cm-1; (+)-ESI-HRMS. Calcd for 
C23H28N2NaO7S+ (M+Na+): 499.1509. Found: 499.1529. 
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Synthesis of 7 
 
A suspension of compound 6 (95.3 mg, 0.2 mmol) and NaI (600 mg, 4.00 mmol) in 
acetone (4 mL) was refluxed for 12 h. After cooling down to room temperature, the 
reaction was diluted with CHCl3. The resulting mixture was washed with brine and 
then dried over Na2SO4. After concentration under reduced pressure, the residue was 
recrystallized from AcOEt-hexane to give compound 7 as white solid (95 mg, 94% 
yield). []20D = –9.5 (c = 0.14, CHCl3); Mp. 153–154°C; 1H NMR (400 MHz, CDCl3) 
 1.49–1.57 (m, 2H), 1.77–1.91 (m, 3H), 1.97–2.06 (m, 1H), 3.17 (t, J = 6.8 Hz, 2H), 
3.94 (s, 3H), 4.41 (dd, J = 5.6 Hz, 14.4 Hz, 1H), 4.51 (dd, J = 6.0 Hz, 14.4 Hz, 1H), 
4.68–4.74 (m, 1H), 6.71 (dd, J = 5.6 Hz, 6.0 Hz, 1H), 7.01 (d, J = 8.0 Hz, 1H), 7.20–
7.33 (m, 5H), 7.51 (dd, J = 8.0 Hz, 8.0 Hz, 1H), 7.97 (dd, J = 1.6 Hz, 8.0 Hz, 1H), 
8.18 (d, J = 8.0 Hz, 1H), 8.40 (d, J = 1.6 Hz, 1H); 13C NMR (100 MHz, CDCl3)  6.4, 
26.5, 31.6, 32.9, 43.7, 52.4, 53.5, 127.6, 127.7 (2C), 127.9, 128.7 (2C), 128.9, 130.6, 
131.7, 132.8, 134.0, 137.7, 166.2, 166.5, 171.3; IR (ATR)  3292, 2927, 1722, 1634, 
1538, 1438, 1299, 1260, 729, 697 cm-1; (+)-ESI-HRMS. Calcd for C22H25IN2NaO4+ 
(M+Na+): 531.0751. Found: 531.0756. 
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Synthesis of (1S,2R)-8  
 
(1S,2R)-2-phenylcyclopropane-1-amine hydrochloride was prepared using the 
reported procedure. To a stirred solution of (1S,2R)-2-phenylcyclopropane-1-amine 
hydrochloride (225 mg, 1.33 mmol) and NEt3 (0.56 mL, 4.00 mmol) in CH2Cl2 (13.3 
mL) at room temperature was added o-nosyl chloride (354.6 mg, 1.60 mmol). The 
reaction mixture was kept stirring for 4 h at room temperature. To consume the 
unreacted 2-nosyl chloride, N,N-dimethylpropane-1,3-diamine (0.165 mL, 1.33 
mmol) was added and the reaction was stirred for 1 h. After dilution with AcOEt, the 
resulting mixture was washed with 1M aq. HCl, sat. aq. NaHCO3 and brine, and then 
dried over Na2SO4. After concentration under reduced pressure, the residue was 
purified by silica gel column chromatography (SiO2, n-hexane/EtOAc = 3/1) to give 
(1S,2R)-8 (309 mg, 73% yield). Stereoscopic data was identical to the reported data. 
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Synthesis of 9 
 
To a stirred suspension of compound (1S,2R)-8 (64 mg, 0.2 mmol) and K2CO3 (55.3 
mg, 0.4 mmol) in DMF (1 mL) at room temperature was added 7 (152.5 mg, 0.3 
mmol), and the resulting mixture was stirred for 24 h at the same temperature. The 
reaction was diluted with AcOEt/n-hexane (4/1) and the mixture was washed with 
water (x2) and brine, and then dried over Na2SO4. After concentration in vacuo, the 
obtained residue was purified by silica gel column chromatography (SiO2, 
n-hexane/EtOAc = 1/1 to 1/2) to give compound 9 (190.3 mg, 91% yield) as white 
amorphous. []20D = 13.9 (c = 2.64, CHCl3); 1H NMR (400 MHz, CDCl3)  1.10–2.15 
(m, 9H), 2.60–2.66 (m, 1H), 3.30– 3.40 (m, 1H), 3.43–3.52 (m, 1H), 3.91 (s, 3H), 
4.47 (d, J = 5.6 Hz, 1H), 4.60–4.68 (m, 1H), 6.56 (broad peak, 1H), 6.92–6.97 (m, 
2H), 7.00 (d, J = 8.0 Hz, 1H), 7.16–7.33 (m, 8H), 7.50–7.72 (m, 4H), 7.97 (dd, J = 1.6 
Hz, 8.0 Hz, 1H), 8.04 (d, J = 8.0 Hz, 1H), 8.16–8.20 (m, 1H), 8.42–8.45 (m, 1H); 13C 
NMR (100 MHz, CDCl3)  16.0, 22.4, 24.9, 27.8, 31.9, 38.4, 43.5, 49.7, 52.2, 53.6, 
124.0, 126.0 (2C), 126.4, 127.4, 127.6 (2C), 128.0, 128.4 (2C), 128.6 (2C), 128.7, 
130.5, 131.4, 131.6, 131.7, 132.6, 132.9, 133.7, 134.0, 137.9, 139.2, 147.9, 166.2, 
166.5, 171.4; IR (ATR)  3285, 1722, 1636, 1542, 1439, 1370, 1259, 1159, 747, 698 
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cm-1; (+)-ESI-HRMS. Calcd for C37H38N4NaO8S+ (M+Na+): 721.2303. Found: 
721.2325. 
Synthesis of 10 
 
A suspension of compound 9 (33.0 mg, 0.0472 mmol), Cs2CO3 (61.6 mg, 0.189 
mmol), and SiliaMetS Thiol (1.41 mmol/g) (134 mg, 0.189 mmol) in CH3CN (1.2 
mL) were stirred for 48 h at room temperature. The yellow suspension was directly 
purified by silica gel column chromatography (SiO2, CHCl3/MeOH = 20/1 to 10/1) to 
give compound 10 (14.9 mg, 62% yield) as colorless oil. []20D = 16.2 (c = 2.4, 
CHCl3); 1H NMR (400 MHz, CDCl3)  0.90–1.06 (m, 2H), 1.40–1.60 (m, 4H), 1.80– 
2.03 (m, 4H), 2.28–2.32 (m, 1H), 2.69–2.76 (m, 2H), 3.94 (s, 3H), 4.41 (dd, J = 5.6 
Hz, 14.8 Hz, 1H), 4.50 (dd, J = 6.0 Hz, 15.2 Hz, 1H), 4.66–4.72 (m, 1H), 6.87 (dd, J 
= 5.6 Hz, 6.0 Hz, 1H), 7.00–7.03 (m, 2H), 7.08 (d, J = 7.2 Hz, 1H), 7.11–7.15 (m, 
1H), 7.21–7.32 (m, 6H), 7.48–7.54 (m, 2H), 7.98–8.00 (m, 1H), 8.16–8.19 (m, 1H), 
8.40–8.42 (m, 1H); 13C NMR (100 MHz, CDCl3)  16.8, 23.2, 24.8, 29.4, 32.7, 41.4, 
43.6, 49.0, 52.4, 53.6, 125.5, 125.8 (2C), 127.6, 127.7 (2C), 127.9, 128.2 (2C), 128.7 
(2C), 128.9, 130.6, 131.7, 132.7, 134.1, 137.8, 142.1, 166.2, 166.3, 171.4; IR (ATR)  
3282, 2925, 1725, 1635, 1538, 1438, 1258, 729, 696 cm-1; (+)-ESI-HRMS. Calcd for 
C31H36N3O4+ (M+H+): 514.2700. Found: 514.2703. 
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Synthesis of 11 
 
This compound was prepared using the synthetic procedure for compound 9 (76% 
yield). White amorphous; []20D = –18.6 (c = 4.04, CHCl3); 1H NMR (400 MHz, 
CDCl3)  1.15–2.10 (m, 9H), 2.60–2.65 (m, 1H), 3.30–3.38 (m, 1H), 3.46–3.54 (m, 
1H), 3.90 (s, 3H), 4.47 (d, J = 6.0 Hz, 1H), 4.60–4.66 (m, 1H), 6.52 (t, J = 6.0 Hz, 
1H), 6.93 (d, J = 7.2 Hz, 2H), 7.00 (d, J = 8.0 Hz, 1H), 7.16–7.30 (m, 8H), 7.50– 7.72 
(m, 4H), 7.97 (d, J = 8.4 Hz, 1H), 8.04 (d, J = 7.6 Hz, 1H), 8.18 (d, J = 7.6 Hz, 1H), 
8.45 (s, 1H); 13C NMR (100 MHz, CDCl3)  16.0, 22.3, 24.9, 27.7, 31.7, 38.3, 43.6, 
49.5, 52.3, 53.6, 124.1, 126.0 (2C), 126.5, 127.4, 127.6 (2C), 128.0, 128.5 (2C), 128.7 
(2C), 128.8, 130.5, 131.5, 131.6, 131.7, 132.7, 133.0, 133.7, 134.0, 137.9, 139.2, 
147.9, 166.2, 166.5, 171.3; IR (ATR)  1724, 1637, 1543, 1261, 1160, 730, 696, 620, 
608 cm-1; (+)-ESI-HRMS. Calcd for C37H38N4NaO8S+ (M+Na+): 721.2303. Found: 
721.2308. 
 
Synthesis of 12 
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This compound was prepared using the synthetic procedure for compound 10 (76% 
yield). Colorless oil; []20D = –18.9 (c = 3.6, CHCl3 ); 1H NMR (400 MHz, CDCl3)  
0.97–1.01 (m, 1H), 1.12–1.17 (m, 1H), 1.40–1.49 (m, 2H), 1.60–1.68 (m, 2H), 1.80–
2.03 (m, 3H), 2.30–2.36 (m, 1H), 2.75–2.84 (m, 2H), 3.90 (s, 3H), 4.39 (dd, J = 6.8 
Hz, 14.8 Hz, 1H), 4.48 (dd, J = 6.8 Hz, 14.8 Hz, 1H), 4.70–4.76 (m, 1H), 7.00–7.03 
(m, 2H), 7.15 (dd, J = 6.8 Hz, 6.8 Hz, 1H), 7.20–7.36 (m, 8H), 7.46–7.50 (m, 2H), 
7.96–7.99 (m, 1H), 8.16 (d, J = 8.0 Hz, 1H), 8.42 (d, J = 2.0 Hz, 1H); 13C NMR (100 
MHz, CDCl3)  16.0, 23.0, 24.1, 28.4, 32.5, 40.8, 43.6, 48.7, 52.4, 53.4, 125.9 (2C), 
127.5, 127.7 (2C), 128.0, 128.3 (2C), 128.7 (2C), 128.8, 130.5, 131.7, 132.7, 134.0, 
137.8, 141.4, 166.2, 166.5, 171.6; IR (ATR)  3297, 2931, 1725, 1637, 1541, 1439, 
1264, 732, 697 cm-1; (+)-ESI-HRMS. Calcd for C31H36N3O + (M+H+): 514.2700. 
Found: 514.2721.  
 
Synthesis of 14 
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A solution of 9 (49.0 mg, 0.07 mmol) and 1M LiOH (0.14 mL, 0.14 mmol) in 
MeOH/THF (1/1) (1.4 mL) was stirred at 40 °C. After 16 h, the resulting mixture was 
acidified with 1M aq. HCl and the mixture was extracted with CHCl3 and then 
organic layer was dried over Na2SO4. After concentration in vacuo, almost pure 
carboxylic acid was obtained in quantitative yield. The obtained residue was used for 
the next reaction without purification. 
To a stirred solution of the crude carboxylic acid derivative, benzotriazol-1-yl- 
oxytripyrrolidinophosphonium-hexafluorophosphat (PyBOP) (72.8 mg, 0.14 mmol), 
and i-Pr2NEt (49 μL mL, 0.28 mmol) in DMF (0.7 mL) at 0 °C was added b-alanine 
dimer 13 (29.5 mg, 0.14 mmol), and the resulting mixture was stirred for 40 h at room 
temperature. The reaction was diluted with AcOEt/n-hexane (4/1) and the resulting 
mixture was washed with 1M aq. HCl solution, sat. aq. NaHCO3 solution, water, and 
brine, and then dried over Na2SO4. After concentration under reduced pressure, the 
obtained residue was purified by silica gel column chromatography 
(CHROMATOREX NH-DM1020, CHCl3/MeOH = 80/1) to give compound 14 (44.7 
mg, 76% yield) as colorless oil. []20D = –49.2 (c = 1.6, CHCl3); 1H NMR (400 MHz, 
CDCl3)  1.10–2.11 (m, 9H), 2.43–2.55 (m, 4H), 2.59–2.65 (m, 1H), 3.24–3.38 (m, 
1H), 3.40–3.52 (m, 3H), 3.61 (s, 3H), 3.60–3.70 (m, 2H), 4.40 (dd, J = 5.6 Hz, 14.8 
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Hz, 1H), 4.46 (dd, J = 6.0 Hz, 14.8 Hz, 1H), 4.63–4.70 (m, 1H), 6.46 (dd, J = 5.6 Hz, 
6.0 Hz, 1H), 6.88–6.95 (m, 3H), 7.14–7.70 (m, 14H), 7.87–8.00 (m, 3H), 8.22 (s, 1H); 
13C NMR (100 MHz, CDCl3)  16.0, 22.6, 24.9, 27.9, 31.7, 33.8, 35.0, 35.6, 36.3, 
38.3, 43.4, 49.8, 51.8, 53.8, 124.1, 125.4, 126.0 (2C), 126.5, 127.3, 127.5 (2C), 128.4 
(2C), 128.6 (2C), 128.8, 130.4, 130.6, 131.5, 131.5, 132.8, 133.7, 133.8, 134.6, 138.0, 
139.2, 147.8, 166.9, 166.9, 171.7, 171.9, 172.9; IR (ATR)  3316, 1737, 1644, 1542, 
1438, 1371, 770, 699, 671, 633 cm-1; (+)-ESI-HRMS. Calcd for C43H48N6NaO10S+ 
(M+Na+): 863.3050. Found: 863.3048. 
Synthesis of 16 
 
A solution of 14 (44.7 mg, 0.053 mmol) and 1M LiOH (0.106 mL, 0.106 mmol) in 
MeOH/THF (1/1) (1.06 mL) was stirred at 40 °C. After 16 h, the resulting mixture 
was acidified with 1M aq. HCl and the mixture was extracted with CHCl3 and then 
organic layer was dried over Na2SO4. After concentration in vacuo, almost pure 
carboxylic acid was obtained in quantitative yield. The obtained residue was used for 
the next reaction without purification. 
A solution of obtained carboxylic acid derivative (22.1 mg, 0.0267 mmol), 15 (14.9 
mg, 0.0267 mmol), 
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benzotriazol-1-yl-oxytripyrrolidinophosphonium-hexafluorophosphate (PyBOP) (27.8 
mg, 0.0534 mmol), and i-Pr2NEt (0.019 mL, 0.107 mmol) in DMF (0.54 mL) was 
stirred for 24 h at room temperature. The reaction was diluted with CHCl3/i-PrOH 
(1/1) and the resulting mixture was washed with 1M aq. HCl solution, sat. aq. 
NaHCO3 solution, and water, and then dried over Na2SO4. After concentration under 
reduced pressure, the obtained residue was purified by silica gel column 
chromatography (CHROMATOREX NH-DM1020, CHCl3/MeOH = 60/1 to 30/1) to 
give compound 16 (26.6 mg, 75% yield) as pale brown solid. Mp. 141–142°C; []20D 
= –29.8 (c = 0.88, CHCl3); IR (ATR)  3292, 2924, 1645, 1543, 1437, 1404, 1252, 
1108, 748, 608 cm-1; (+)-ESI-HRMS. Calcd for C67H72N14NaO14S+ (M+Na+): 
1351.4971. Found: 1351.4917. Although all signals were detected as broad peaks in 
the 1H NMR analysis (CDCl3) probably due to the high molecular weight, an 
analyzable chart was obtained. See supporting information for the 1H NMR chart. 
 
Synthesis of 3a 
 
To a stirred solution of 16 (11.0 mg, 0.0083 mmol), K2CO3 (4.6 mg, 0.033 μmol) in 
DMF (0.3 mL) was added thiophenol (2.1 μL, 0.021 mmol) and the resulting solution 
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was stirred for 1 h at room temperature. The yellow solution was directly purified by 
silica gel column chromatography (SiO2, CHCl3/MeOH = 20/1 to 10/1) to give 
compound 3a (6.5 mg, 65% yield) as colorless solid. []20D = –41.4 (c = 0.48, 
CHCl3); IR (ATR)  3295, 2924, 2853, 1644, 1540, 1436, 1404, 1254, 1205, 1108, 
754, 699, 606 cm-1; (+)-ESI-HRMS. Calcd for C61H70N13O+ (M+H+): 1144.5363. 
Found: 1144.5350. Although all signals 10 were detected as broad peaks in the 1H 
NMR analysis (CDCl3) probably due to the high molecular weight, 3 an analyzable 
chart was obtained.  
 
Synthesis of 21 
 
To a stirred solution of 19 (181.7 mg, 0.5 mmol), 20 (187.7 mg, 0.6 mmol), and 
HATU (380.2 mg, 1 mmol) in DMF (5 mL) at room temperature was added i-Pr2NEt 
(0.35 mL, 2 mmol), and the resulting mixture was stirred for 48 h at the same 
temperature. The reaction was quenched by the addition of 1M aq. KHSO4 solution 
and the mixture was extracted with CH2Cl2. The organic layer was washed with brine 
and dried over Na2SO4. After concentration under reduced pressure, the obtained 
residue was purified by silica gel column chromatography (SiO2, hexane/AcOEt = 
1/3) to give compound 21 (111.9 mg, 36% yield) as yellow amorphous. Mp. 155–
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156°C; 1H NMR (400 MHz, CDCl3)  1.26 (s, 9H), 3.82 (s, 3H), 3.91 (s, 3H), 3.93 (s, 
3H), 3.97 (s, 3H), 4.07 (s, 3H), 6.35 (s, 1H), 6.72 (s, 1H), 6.78 (d, J = 2.0 Hz, 1H), 
6.84 (s, 1H), 7.00 (s, 1H), 7.43 (d, J = 2.0 Hz, 1H), 7.48 (s, 1H), 7.67 (s, 1H), 8.41 (s, 
1H), 8.61 (d, J = 0.8 Hz, 1H), 8.98 (s, 1H); 13C NMR (100 MHz, CDCl3)  28.4 (3C), 
29.7, 35.9, 36.7, 36.8, 51.1, 80.3, 103.6, quant. 104.3, 108.4, 114.2, 119.3, 119.5, 
119.8, 120.8, 121.0, 121.9, 122.1, 123.4, 133.5, 135.7, 150.1, 153.5, 155.5, 158.6, 
158.9, 161.6; IR (ATR)  3318, 2926, 1698, 1658, 1587, 1539, 1440, 1404, 1367, 
1250, 1205, 1162, 1110, 772, 733 cm-1; (+)-ESI-HRMS. Calcd for C29H35N9NaO7+ 
(M+Na+): 644.2557. Found: 644.2553. 
 
Synthesis of 17 
 
To a stirred solution of 21 (186.5 mg, 0.3 mmol) in CH2Cl2 (6.2 mL) at 0 °C was 
added 4M HCl in dioxane (0.75 mL) and the resulting mixture was stirred at room 
temperature. After 19 h, organic solvent was removed and the residue was washed 
with ether to give 17 (168 mg, quant.) as yellow solid, which was used for the next 
reaction without further purification. Mp. 188–189°C; 1H NMR (400 MHz, CD3OD) 
 3.79 (s, 3H), 3.89 (s, 3H), 3.92 (s, 3H), 3.98 (s, 3H), 4.09 (s, 3H), 6.93 (d, J = 2.4 
Hz, 1H), 6.98 (s, 1H), 7.02 (d, J = 2.4 Hz, 1H), 7.13 (d, J = 2.4 Hz, 1H), 7.36 (d, J = 2 
Hz, 1H), 7.49–7.53 (m, 2H), 8.43 (dd, J = 1.2 Hz, 8.0 Hz, 1H), 8.73 (dd, J = 1.2 Hz, 
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4.0 Hz, 1H). (Protons in NH2 and one amide NH proton could not be detected in 
CD3OD); IR (ATR)  3364, 1671, 1633, 1554, 1435, 1404, 1258, 1206, 1110, 769, 
638, 611 cm-1; (+)-ESI-HRMS. Calcd for C24H27N9O5+ (M+H+): 522.2213. Found: 
522.2238. 
 
Synthesis of 18 
 
 
A solution of 14 (44.7 mg, 0.053 mmol) and 1M LiOH (0.106 mL, 0.106 mmol) in 
MeOH/THF (1/1) (1.06 mL) was stirred at 40 °C. After 16 h, the resulting mixture 
was acidified with 1M aq. HCl and the mixture was extracted with CHCl3 and then 
organic layer was dried over Na2SO4. After concentration in vacuo, almost pure 
carboxylic acid was obtained in quantitative yield. The obtained residue was used for 
the next reaction without purification. 
A solution of obtained carboxylic acid derivative (22.1 mg, 0.0267 mmol), 17 (14.9 
mg, 0.0267 mmol), 
benzotriazol-1-yl-oxytripyrrolidinophosphonium-hexafluorophosphate (PyBOP) (27.8 
mg, 0.0534 mmol), and i-Pr2NEt (0.019 mL, 0.107 mmol) in DMF (0.54 mL) was 
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stirred for 24 h at room temperature. The reaction was diluted with CHCl3/i-PrOH 
(1/1) and the resulting mixture was washed with 1M aq. HCl solution, sat. aq. 
NaHCO3 solution, and water, and then dried over Na2SO4. After concentration under 
reduced pressure, the obtained residue was purified by silica gel column 
chromatography (CHROMATOREX NH-DM1020, CHCl3/MeOH = 60/1 to 30/1) to 
give compound 18 (25.7 mg, 72% yield) as colorless oil. []20D = –35.7 (c = 0.54, 
CHCl3); IR (ATR)  3296, 2925, 1647, 1542, 1441, 1405, 1255, 1117, 670, 626 cm-1; 
(+)-ESI-HRMS. Calcd for C67H72N14NaO14S+ (M+Na+): 1352.4923. Found: 
1352.4918. Although all signals were detected as broad peaks in the 1H NMR 
analysis (CDCl3) probably due to the high molecular weight, an analyzable chart was 
obtained.  
 
 
Synthesis of 3b 
 
To a stirred solution of 18 (12.0 mg, 0.00903 mmol), K2CO3 (5.0 mg, 0.0361 mmol) 
in DMF (0.3 mL) was added thiophenol (2.1 μL, 0.0226 mmol) and the resulting 
solution was stirred for 2 h at room temperature. The yellow solution was directly 
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purified by silica gel column chromatography (SiO2, CHCl3/MeOH = 20/1 to 10/1) to 
give compound 3b (5.7 mg, 55% yield) as colorless solid. []20D = 32.1 (c = 0.57, 
CHCl3); IR (ATR)  3284, 2924, 1643, 1531, 1440, 1404, 1251, 1204, 1107, 750 
cm-1; (+)-ESI- HRMS. Calcd for C60H69N14O10+ (M+H+): 1145.5316. Found: 
1145.5296. Although all signals were detected as broad peaks in the 1H NMR 
analysis (CDCl3) probably due to the high molecular weight, an analyzable chart was 
obtained.  
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Synthesis of 22-COOMe 
 
 
To a stirred solution of rac-8 (191 mg, 0.6 mmol) in DMF (3 mL) at room 
temperature was added K2CO3 (165.8 mg, 1.2 mmol) and methyl 2-iodoacetate 21 
(240.6 mg, 1.2 mmol). The resulting mixture was stirred at room temperature for 2 h. 
The reaction was diluted with ether and the mixture was washed with brine, and then 
dried over Na2SO4. After concentration in vacuo, the obtained residue was purified by 
silica gel column chromatography (SiO2, n-hexane/EtOAc = 2/1) to give 22-COOMe 
(254 mg, 95% yield) as white amorphous. 1H NMR (400 MHz, CDCl3)  1.14–1.43 
(m, 4H), 1.60–1.72 (m, 4H), 2.09–2.14 (m, 1H),2.30 (t, J = 7.6 Hz, 2H), 2.63–2.67 (m, 
1H), 3.29–3.50 (m, 2H), 3.66 (s, 3H), 6.96–6.98 (m, 2H), 7.17–7.28 (m, 3H), 7.75–
7.71 (m, 3H), 8.00 (dd, J = 1.2 Hz, 8.4Hz, 1H); 13C NMR (100 MHz, CDCl3)  24.5, 
24.9, 26.2, 28.1, 33.8, 38.4, 124.0, 126.1 (2 C), 126.5, 128.5 (2 C), 131.4, 131.7, 
133.1, 133.6, 139.3, 147.9, 173.9; IR (ATR)  2946, 1731, 1541, 1437, 1345, 1159, 
1126, 1060, 851, 743, 698 cm-1; (+)-ESI-HRMS. Calcd for C22H26N2O7S+ (M+Na+): 
469.1404. Found: 469.1409. 
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Synthesis of 22 
 
 
 
A solution of 22-COOMe (226.8 mg, 0.5 mmol) and 1M LiOH (1 mL, 1 mmol) in 
MeOH (5 mL) was stirred at 50 °C. After 16 h, the resulting mixture was acidified 
with 1M aq. HCl and the mixture was extracted with CHCl3 and then organic layer 
was dried over Na2SO4. After concentration in vacuo, The obtained residue was 
purified by silica gel column chromatography (SiO2, n-hexane/EtOAc = 1/2) to give 
compound 22 (215 mg, 99% yield) as off-white amorphous. 1H NMR (400 MHz, 
CDCl3)  1.19–1.42 (m, 4H), 1.61–1.70 (m, 4H), 2.09–2.13 (m, 1H), 2.34 (t, J = 7.6 
Hz, 2H), 2.63–2.67 (m, 1H), 3.33–3.49 (m, 2H), 6.96–6.98 (d, J = 7.2 Hz, 2H), 7.19–
7.27 (m, 3H), 7.56–7.71 (m, 3H), 7.98–8.00 (dd, J = 0.8 Hz, 7.6Hz, 1H); 13C NMR 
(100 MHz, CDCl3)  16.1, 24.1, 24.9, 26.0, 28.0, 33.7, 38.4, 50.1, 124.0, 126.0 (2 C), 
126.4, 128.4 (2 C), 131.4, 131.6, 132.9, 133.7, 139.3, 147.9, 179.7; IR (ATR)  2929, 
1705, 1541, 1439, 1345, 1158, 1125, 1079, 1060, 851, 743, 698 cm-1; (+)-ESI-HRMS. 
Calcd for C21H24N2O7S+ (M+Na+): 455.1247. Found: 455.1263. 
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Synthesis of Ns-23 
 
 
 
To a stirred solution of 6-((2-nitro-N-( 2-phenylcyclopropyl)  phenyl) sulfonamido) 
hexanoic acid 22 (129.7 mg, 0.3 mmol), 1-[ Bis( dimethylamino) methylene] 
-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide hexafluorophosphate (HATU) (288.1 
mg, 0.6 mmol) and N,N-diisopropylethylamine (0.31 mL, 1.8 mmol) in DMF (3 mL) 
at 0 °C was added the obtained amine hydrochloride HCl·NH2-PyPy-COOme (93.8 
mg, 0.3 mmol). After 24 h, the reaction was quenched with sat. aq. KHSO4 solution 
and diluted with AcOEt. The resulting mixture was washed with brine, and then dried 
over Na2SO4. After concentration under reduced pressure, the residue was 
recrystallized by NH-silica gel column chromatography from AcOEt-hexane (2/1) to 
give compound Ns-23 as yellow amorphous (132 mg, 64% yield). 1H NMR (400 
MHz, CDCl3)  1.18 (dd, 6.4 Hz, 13.2 Hz, 1H), 1.26–1.35 (m, 3H), 1.66 (dd, J = 8 Hz, 
15.6 Hz, 4H), 2.07–2.12(m, 1H), 2.27–2.31 (t, J = 7.2 Hz, 2H), 2.62 (t, J = 3.2 Hz, 
1H), 3.28–3.47 (m, 2H), 3.76 (s, 3H), 3.83 (s, 3H), 3.86 (s, 3H), 6.72 (d, J = 1.2 Hz, 
1H), 6.82 (d, J = 2 Hz, 1H), 7.13–7.27 (m, 3H), 7.38 (s, 1H), 7.54–7.71 (m, 4H), 7.94 
(d, J = 7.6 Hz, 1H); 13C NMR (100 MHz, CDCl3)  15.9, 24.9, 25.1, 26.0, 28.1, 36.4, 
36.5, 36.6, 38.4, 50.0, 50.9, 104.2, 108.5, 119.5, 120.8, 121.3, 122.0, 124.1, 126.0 (2 
C), 126.4, 128.4 (2 C), 131.4, 131.5, 132.6, 133.8, 139.0, 147.7, 159.0, 161.5, 170.8; 
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IR (ATR)  2947, 1705, 1655, 1543, 1439, 1405, 1366, 1251, 1158, 1108, 1060 cm-1; 
(+)-ESI-HRMS. Calcd for C34H38N6O8S+ (M+H+): 691.2545. Found: 691.2530. 
Synthesis of 23 
 
 
 
To a stirred solution of Ns-23 (55.3 mg, 0.08 mmol), K2CO3 (44.2 mg, 0.32 mmol) in 
DMF (2 mL) was added thiophenol (20.5 µL, 0.2 mmol) and the resulting solution 
was stirred for 4 h at room temperature. The yellow solution was washed with brine, 
NaHCO3 successively, then dried over Na2SO4. The condensed residue was purified 
by silica gel column chromatography (SiO2, CHCl3/MeOH = 10/1) to give compound 
23 (24 mg, 60% yield) as yellow amorphous. IR (ATR)  2929, 1704, 1650, 1552, 
1437, 1403, 1361, 1248, 1195, 1151, 1105, 1059, 822 cm-1; (+)-ESI-HRMS. Calcd for 
C28H35N5O4+ (M+H+): 507.2846. Found: 507.2856. Although all signals were 
detected as broad peaks in the 1H NMR analysis (CDCl3) probably due to the high 
molecular weight, an analyzable chart was obtained.  
 
Synthesis of Ns-24. 
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To a stirred solution of 6-((2-nitro-N-( 2-phenylcyclopropyl)  phenyl) sulfonamido) 
hexanoic acid 22 (43.3 mg, 0.1 mmol), 1-[ Bis( dimethylamino) methylene] 
-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide hexafluorophosphate (HATU) (76 mg, 
0.2 mmol) and N,N-diisopropylethylamine (0.1 mL, 0.6 mmol) in DMF (1 mL) at 
0 °C was added the obtained amine hydrochloride HCl·NH2-PyIm-COOme (31.4 mg, 
0.1 mmol). After 24 h, the reaction was quenched with sat. aq. KHSO4 solution and 
diluted with AcOEt. The resulting mixture was washed with brine, and then dried 
over Na2SO4. After concentration under reduced pressure, the residue was 
recrystallized by silica gel column chromatography (SiO2, CHCl3/MeOH = 20/1) 
twice to give compound Ns-24 as yellow amorphous (104 mg, 75% yield). 1H NMR 
(400 MHz, CDCl3)  1.18–1.40 (m, 4H), 1.66–1.73 (m, 4H), 2.09–2.12(m, 1H), 2.27–
2.31 (t, J = 7.2 Hz, 2H), 2.63–2.65 (t, J = 3.2 Hz, 1H), 3.32–3.45 (m, 2H), 3.90 (s, 
3H), 3.91 (s, 3H), 3.99 (s, 3H), 6.55 (d, J = 2 Hz, 1H), 6.90 (d, J = 6.8 Hz, 2H), 7.18–
7.28 (m, 3H), 7.36 (s, 1H), 7.55–7.67 (m, 4H), 7.98 (d, J = 5.6 Hz, 1H); 13C NMR 
(100 MHz, CDCl3)  15.9, 24.9, 25.0, 26.0, 28.0, 35.8, 36.3, 36.6, 38.4, 50.0, 52.1, 
103.6, 114.7, 120.4, 121.6, 121.8, 124.0, 125.9 (2 C), 126.3, 128.3 (2 C), 131.0, 131.4, 
132.7, 133.6, 137.2, 139.2, 147.8, 158.4, 158.9, 170.4; IR (ATR)  2949, 1713, 1656, 
1540, 1461, 1436, 1403, 1370, 1277, 1202, 1158, 1125, 1060, 909 cm-1; 
(+)-ESI-HRMS. Calcd for C33H37N7O8S+ (M+H+): 692.2497. Found: 692.2493. 
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Synthesis of 24. 
 
 
 
To a stirred solution of Ns-24 (55.3 mg, 0.08 mmol), K2CO3 (44.2 mg, 0.32 mmol) in 
DMF (2 mL) was added thiophenol (20.5 µL, 0.2 mmol) and the resulting solution 
was stirred for 4 h at room temperature. The yellow solution was washed with brine, 
NaHCO3 successively, then dried over Na2SO4. The condensed residue was purified 
by silica gel column chromatography (SiO2, CHCl3/MeOH = 10/1) to give compound 
24 (60 mg, quant.) as yellow amorphous. IR (ATR)  2925, 1715, 1658, 1542, 1461, 
1438, 1404, 1372, 1278, 1127, 741, 698, 629 cm-1; (+)-ESI-HRMS. Calcd for 
C27H34N6O4+ (M+H+): 507.2714. Found: 507.2709. Although all signals were 
detected as broad peaks in the 1H NMR analysis (CDCl3) probably due to the high 
molecular weight, an analyzable chart was obtained.  
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Synthesis of Ns-25. 
 
 
 
To a stirred solution of 6-((2-nitro-N-( 2-phenylcyclopropyl)  phenyl) sulfonamido) 
hexanoic acid 22 (51.9 mg, 0.12 mmol), 1-[ Bis( dimethylamino) methylene] 
-1H-1,2,3-triazolo[4,5-b] pyridinium 3-oxide hexafluorophosphate (HATU) (76 mg, 
0.2 mmol) and N,N-diisopropylethylamine (0.034 mL, 0.2 mmol) in DMF (0.5 mL) at 
0 °C was added the obtained amine NH2-ImPy-COOMe (27.7 mg, 0.1 mmol). After 
24 h, the reaction was diluted with AcOEt. The resulting mixture was washed with sat. 
aq. Na2CO3 aq, sat. aq. KHSO4 solution, water, and brine, and then dried over Na2SO4. 
After concentration under reduced pressure, the residue was recrystallized by silica 
gel column chromatography (CHCl3/MeOH, 50/1, NH-silica, then SiO2, 
CHCl3/MeOH = 40/1) to give compound Ns-25 as yellow amorphous (28.9 mg, 42% 
yield). 1H NMR (400 MHz, CDCl3)  1.16–1.45 (m, 4H), 1.66–1.77 (m, 4H), 2.09–
2.13(m, 1H), 2.33–2.37 (t, J = 7.6 Hz, 2H), 2.64–2.67 (m, 1H), 3.31–3.52 (m, 2H), 
3.81 (s, 3H), 3.90 (s, 3H), 4.04 (s, 3H), 6.82 (d, J = 2 Hz, 1H), 6.96 (d, J = 8 Hz, 2H), 
7.17–7.25 (m, 3H), 7.40 (s, 1H), 7.53–7.71 (m, 4H), 8.00 (d, J = 8.4 Hz, 1H); 13C 
NMR (100 MHz, CDCl3)  16.1, 24.9, 24.9, 26.1, 28.1, 29.7, 35.6, 36.3, 36.8, 50.0, 
51.1, 108.2, 114.2, 120.0, 121.6, 121.1, 124.0, 126.0 (2 C), 126.5, 128.5 (2 C), 131.5, 
131.6, 133.0, 133.6, 135.8, 139.3, 147.9, 155.9, 161.5, 170.1; IR (ATR)  2926, 1672, 
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1540, 1447, 1371, 1256, 1197, 1160, 1118, 1061, 911, 733 cm-1; (+)-ESI-HRMS. 
Calcd for C33H37N7O8SNa+ (M+Na+): 714.2317. Found: 714.2306. 
 
Synthesis of 25. 
 
 
 
To a stirred solution of Ns-25 (12.4 mg, 0.018 mmol), K2CO3 (10 mg, 0.045 mmol) in 
DMF (0.45 mL) was added thiophenol (4.6 µL, 0.045 mmol) and the resulting 
solution was stirred for 4 h at room temperature. The yellow solution was washed 
with brine, extracted with AcOEt, then dried over Na2SO4. The condensed residue 
was purified by silica gel column chromatography (NH-silica, CHCl3; then SiO2, 
CHCl3/MeOH = 20/1 to 10/1) to give compound 25 (2.9 mg, 32 %) as yellow 
amorphous. 1H NMR (400 MHz, CDCl3)  0.83–0.88 (m, 1H), 0.96–1.01 (m, 1H), 
1.10–1.14 (m, 1H), 1.37–1.45 (m, 2H), 1.53–1.59 (m, 2H), 1.70–1.77 (m, 2H), 2.34–
2.38 (m, 3H), 2.75–2.78 (m, 2H), 3.81 (s, 3H), 3.91 (s, 3H), 4.05 (s, 3H), 6.77 (d, J = 
2.4 Hz, 1H), 7.043 (d, J = 8 Hz, 2H), 7.13–7.17 (m, 1H), 7.23–7.26 (m, 3H), 7.41 (s, 
2H), 7.82 (s, 1H), 8.78 (s, 1H); IR (ATR)  2925, 2363, 1703, 1670, 1541, 1446, 1404, 
1255, 1196, 1117, 913, 749, 698 cm-1; (+)-ESI-HRMS. Calcd for C27H34N6O4+ 
(M+H+): 507.2714. Found: 507.2711.  
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Synthesis of Ns-26 
 
 
 
To a stirred solution of amine hydrochloride HCl·NH2-PyIm-COOme (80.0 mg, 0.144 
mmol), hexanoic acid 22 (56.2 mg, 0.13 mmol), and i-Pr2NEt (45 µL, 0.26 mmol) in 
DMF (0.87 mL) at room temperature was added HATU (98.9 mg, 0.26 mmol) and the 
resulting mixture was stirred for 12 h at room temperature. After dilution with 
CHCl3/i-PrOH (1/1), the resulting mixture was washed with sat. aq. Na2CO3, 1N HCl, 
H2O, and brine and then dried over Na2SO4. After concentration in vacuo, the 
obtained residue was purified by silica gel column chromatography (CHCl3/MeOH, 
60/1, NH-silica) to give the target compound (76.8 mg, 63% yield) as yellow 
amorphous. Formation of the target molecule was confirmed by ESI Mass analysis: 
m/z: [M+Na]+ 957. 
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Synthesis of 26 
 
 
 
To a stirred suspension of Ns adduct Ns-26 (12 mg, 0.0126 mmol) and K2CO3 (6.6 
mg, 0.048 mmol) in DMF (0.3 mL) at room temperature was added thiophenol (3 mL, 
0.03 mmol). The resulting mixture was stirred for 2 h at the same temperature. The 
reaction was directly purified by silica gel column chromatography (CHCl3/MeOH, 
50/1, NH-silica) to give the target compound 26(5.8 mg, 61% yield) as yellow 
amorphous. IR (ATR)  2923, 2361, 1647, 1578, 1437, 1403, 1258, 1107, 736 cm-1; 
(+)-ESI-TOF Mass. m/z: [M+H]+ Calcd for C40H48N9O6+ 750.3722; Found. 750.3737. 
 
Synthesis of Ns-26-COOH 
 
 
 
To a stirred solution of Ns-26 (100 mg, 0.107 mmol) in MeOH/THF (1 mL/1 mL) at 
room temperature was added 1M aq. LiOH (0.2 mL, 0.2 mmol) and the resulting 
mixture was stirred at 40 °C. After 6 h, the reaction was cooled down to room 
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temperature and 1N HCl was added to the reaction. The mixture was extracted with 
CHCl3 and the combined organic layers were dried over Na2SO4. After concentration 
in vacuo, the obtained residue was purified by silica gel column chromatography 
(CHCl3/MeOH, 30/1 to 20/1, SiO2, 2 times) to give the target compound 
Ns-26-COOH (28.9 mg, 31% yield). Starting material Ns-26 was also recovered 
(40.8 mg, 41% yield). Formation of the target molecule was confirmed by ESI Mass 
analysis: m/z: [M+Na]+ 943. 
 
Synthesis of Ns-28 
 
 
To a stirred solution of Ns-26-COOH (25.5 mg, 0.028 mmol) and HATU (21.3 mg, 
0.056 mmol) in DMF (0.56 mL) at room temperature was added 
N,N-dimethylpropane 1,3-diamine (18 µL, 0.14 mmol), and the resulting mixture was 
stirred for 20 h at the same temperature. After dilution with AcOEt, the mixture was 
washed with sat. aq. Na2CO3, water, brine, and then dried over Na2SO4. After 
concentration in vacuo, the obtained residue was purified by silica gel column 
chromatography (CHCl3/MeOH, 30/1 to 20/1, NH-silica) to give the target compound 
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Ns-28 (18.4 mg, 65% yield). Formation of the target molecule was confirmed by ESI 
Mass analysis: m/z: [M+H]+ 1005. 
 
Synthesis of 28 
 
 
To a stirred suspension of Ns adduct Ns-28 (11.8 mg, 0.0117 mmol) and K2CO3 (6.5 
mg, 0.047 mmol) in DMF (0.3 mL) at room temperature was added thiophenol (3 mL, 
0.035 mmol). The resulting mixture was stirred for 2 h at the same temperature. The 
reaction was directly purified by silica gel column chromatography (CHCl3/MeOH, 
50/1, NH-silica) to give the target compound 28(2.6 mg, 27% yield) as yellow 
amorphous. Formation of the target molecule was confirmed by ESI Mass analysis: 
m/z: [M+H]+ 820. 
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Synthesis of 27 
 
 
Compound 27 was prepared using the same method as that for compound 26. 
Formation of the target molecule was confirmed by ESI Mass analysis: m/z: [M+H]+ 
1006. 
 
Synthesis of 29 
 
Compound 29 was prepared using the same method as that for compound 28. 
Formation of the target molecule was confirmed by ESI Mass analysis: m/z: [M+H]+ 
821. 
  
 72 
References 
 
[1] Watson, J.D., Crick.F.H.C. Nature. 1953, 171, 737-738 
[2] Dervan, P.B., Kurmis, A.A., Finn, P.B. DNA-Target Mol. Ther. Agents. 2018, 7, 
298. 
[3] Waring, M. J., Wakelin, L. P. G. Wiley-VCH: Weinheim, Germany. 2003; 1, 1-17. 
[4] Lerman, L. S. J. Mol. Biol. 1961, 3, 18-30. 
[5] Chaires J. B., Waring M. J. Methods in enzymology. 2001, 340 
[6] Waring M. Sequence-Specific DNA Binding Agents. 2006, 109-129 
[8] Kopka, M. L., Yoon, C., Goodsell, D., Pjura, P., Dickerson, R. E. Proc. Natl. Acad. 
Sci. U. S. A. 1985, 82, 1376- 1380. 
[9] Coll, M., Frederick, C. A., Wang, A. H., Rich, A. A. Proc. Natl. Acad. Sci. U. S. A. 
1987, 84, 8385-8389. 
[10] Chen, X., Ramakrishnan, B., Rao, S. T., Sundaralingam, M. Nat. Struct. Biol. 
1994, 1, 169- 175. 
[11] Shieh, H. S., Berman, H. M., Dabrow, M., Neidle, S. Nucleic Acids Res. 1980, 8, 
85. 
[12] Kopka, M. L., Yoon, C., Goodsell, D., Pjura, P., Dickerson, R. E. Proc. Natl. 
Acad. Sci. U. S. A. 1985, 82, 1376- 1380. 
[13] Mrksich M., Dervan P.B. J Am Chem Soc. 1993, 115, 2572–2576. 
[14] (a) Wade W.S., Mrksich M., Dervan P.B. J Am Chem Soc. 1992, 114, 8783–8794; 
(b) Mrksich M., Wade W.S., Dwyer T.J., Geierstanger B.H., Wemmer D.E., Dervan 
P.B. PNAS. 1992, 89, 7586–7590; (c) Wade W.S., Mrksich M., Dervan P.B. 
Biochemistry. 1993, 32, 11385–11389. 
[15] Shi, Y., and Whetstine, J. R. Molecular Cell. 2007, 25, 1-14. 
[16] Rotili D., Mai A. Genes & Cancer. 2011, 2(6), 663–679.  
[17] Allfrey V.G., Faulkner R., Mirsky A.E. Proc Natl Acad Sci USA. 1964,  51, 
786-794. 
[18] Luger K., Mader A.W., Richmond R.K., Sargent D.F., Richmond T.J. Nature. 
1997, 389, 251-260. 
[19] Bannister A.J., Schneider R., Kouzarides T. Cell. 2002, 109, 801-806. 
[20] Greer E.L., Shi Y. Nature Reviews Genetics. 2012, 13, 343-357. 
[21] Margueron R., Trojer P., Reinberg D. CurrOpin Genet Dev. 2005, 15, 163-176. 
 73 
[22] Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A., Casero, R. 
A., and Shi, Y. Cell. 2004, 119, 941-953. 
[23] Culhane, J. C., and Cole, P. A. Current Opinion in Chemical Biology 2007, 11, 
561-568. 
[24] Ruthenburg, A. J., Li, H., Patel, D. J., and Allis, C. D. Nat Rev Mol Cell Biol 
2007, 8, 983-994. 
[25] Scoumanne, A., and Chen, X. Journal of Biological Chemistry 2007, 282, 
15471-15475. 
[26] Schenk, T., Chen, W. C., Göllner, S., Howell, L., Jin, L., Hebestreit, K., Klein, 
H.-U., Popescu, A. C., Burnett, A., Mills, K., et al. Nat Med 2012, 18, 605-611. 
[27] Ding, J., Zhang, Z. M., Xia, Y., Liao, G. Q., Pan, Y., Liu, S., Zhang, Y., and Yan, 
Z. S. Br J Cancer 2013, 109, 994-1003. 
[28] Liang Y., Vogel J.L., Narayanan A., Peng H., Krisrie T.M. Nat Med 2009, 15: 
1312-1317. 
[29] Suzuki, M., Yamamoto, M., and Engel, J. D. Mol Cell Biol 2014, 34, 3560-3569. 
[30] Schmidt, D. M. Z., and McCafferty, D. G. Biochemistry 2007, 46, 4408-4416. 
[31] Yang, M., Culhane, J. C., Szewczuk, L. M., Jalili, P., Ball, H. L., Machius, M., 
Cole, P. A., and Yu, H. Biochemistry 2007, 46, 8058-8065. 
[32] Serce, N., Gnatzy, A., Steiner, S., Lorenzen, H., Kirfel, J., and Buettner, R. BMC 
Clin Pathol 2012, 12, 13-13. 
[33] Schulte, J. H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, 
I., Pajtler, K., Klein-Hitpass, L., Kuhfittig-Kulle, S., et al. Cancer Research 2009, 69, 
2065. 
[34] Baird E.E., Dervan P.B., J. Am. Chem. Soc. 1996, 118, 6141–6146. 
[35] Wurtz N.R., Turner J.M., Baird E.E. Org. Lett. 2001, 3, 1201–1203. 
[36] Belitsky J.M., Nguyen D.H., Wurtz N.R. Bioorg. Med. Chem. 2002, 10, 
2767–2774. 
[37] Harki D.A., Satyamurthy N., Stout D.B. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 
13039–13044. 
[38] Jaramillo, D., Liu, Q., Aldrich-Wright, J., Tor, Y. J. Org. Chem. 2004, 69, 
8151-8153.  
[39] D. Ogasawara, Y. Itoh, H. Tsumoto, T. Kakizawa, K. Mino, K. Fukuhara, H. 
Nakagawa, M. Hasegawa,R. Sasaki, T. Mizukami, N. Miyata, and T. Suzuki, Angew. 
 74 
Chem. Int. Ed., 2013, 52, 8620. 
[40] Itoh, Y., Ogasawara, D., Ota, Y., Mizukami, T., Suzuki, T. Comput. Struct. 
Biotechnol. J. 2014, 9, e201402002. 
[41] Cho, S. J., Jensen, N. H., Kurome, T., Kadari, S., Manzano, M. L., Malberg, J. E., 
Caldarone, B., Roth, B. L., and Kozikowski, A. P. J. Med. Chem. 2009, 52, 
1885-1902. 
[42] Edmondson, D. E., Binda, C., Wang, J., Upadhyay, A. K., and Mattevi, A. 
Biochemistry 2009, 48, 4220-4230. 
[43] Jacobs, C. S., and Dervan, P. B. J Med Chem 2009, 52, 7380-7388. 
[44] Sheng, W., LaFleur, M. W., Nguyen, T. H., Chen, S., Chakravarthy, A., Conway, 
J. R., Li, Y., Chen, H., Yang, H., Hsu, P.-H., et al. Cell 2018, 174, 549-563.e19. 
  
 75 
Publication 
 
This thesis is based on the following publication. 
Qin R, Takayanagi S, Kondo Y, Li J, Shiga N, Nakajima M, Shinohara K, Yoda N, 
Suzuki T, Kaneda A, and Nemoto T. Heterocycles 2019, 99, 891.  
 76 
Acknowledgement 
 
I would like to show my appreciation to Professor Tetsuhiro Nemoto who gave me 
opportunities to do my project work. I thank for his helpful advices and critical review 
of all of the manuscripts. 
I wish to express my sincere gratitude to Mr. Ken-ichi Shinohara, Mr. Natsumi Yoda 
and Professor Atsushi Kaneda for many beneficial advices, technical supports and 
fruitful discussion of bioactivity experiments. 
I would like to show appreciation to PIP group members of Ms. Shihori Takayanagi, 
Mr. Yusuke Kondo, Ms. Jiawei Li, Mr. Naoki Shiga and Mr. Masaya Nakajima for 
kind supporting on synthesis of PIP. 
I would like to express my gratitude to Professor Takayoshi Suzuki for many valuable 
advices of discussion on the molecular design.  
I offer my regards to fellow students and all my friends who support me in any 
respect during the completion of the project. 
Lastly, I wish to thank my parents who inspired, encouraged and fully supported me 
through my studies. 
